Kian Fan Chung

List of Publications by Year
in descending order

707 papers	53,080 citations	1296 112 h-index	2584 201 g-index
726 all docs	726 docs citations	726 times ranked	38991 citing authors

#	Article	IF	Citations
1	Mapping atopic dermatitis and antiâ€“IL-22 response signatures to type 2â€“low severe neutrophilic asthma. Journal of Allergy and Clinical Immunology, 2022, 149, 89-101.	1.5	22
2	Associations between lung-deposited dose of particulate matter and culture-positive pulmonary tuberculosis pleurisy. Environmental Science and Pollution Research, 2022, 29, 6140-6150.	2.7	2
3	An altered sputum macrophage transcriptome contributes to the neutrophilic asthma endotype. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1204-1215.	2.7	14
4	Adult Severe Asthma. , 2022, , 383-399.		0
5	Interactions of chemical components in ambient PM2.5 with influenza viruses. Journal of Hazardous Materials, 2022, 423, 127243.	6.5	19
6	Molecular mechanisms of oxidative stress in asthma. Molecular Aspects of Medicine, 2022, 85, 101026.	2.7	90
7	ORMDL3 regulates cigarette smokeâ€“induced endoplasmic reticulum stress in airway smooth muscle cells. Journal of Allergy and Clinical Immunology, 2022, 149, 1445-1457.e5.	1.5	6
8	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. European Respiratory Journal, 2022, 59, 2100142.	3.1	10
9	Association of Differential Mast Cell Activation with Granulocytic Inflammation in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 397-411.	2.5	30
10	A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes. European Respiratory Journal, 2022, 59, 2102603.	3.1	11
11	Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study. European Respiratory Journal, 2022, 59, 2101733.	3.1	13
12	Severe eosinophilic asthma in Chinese Câ€BIOPRED asthma cohort. Clinical and Translational Medicine, 2022, 12, e710.	1.7	4
13	The impacts of ambient relative humidity and temperature on supine position-related obstructive sleep apnea in adults. Environmental Science and Pollution Research, 2022, 29, 50755-50764.	2.7	5
14	Lung toxicity of particulates and gaseous pollutants using ex-vivo airway epithelial cell culture systems. Environmental Pollution, 2022, 305, 119323.	3.7	9
15	Long-COVID severe refractory cough: discussion of a case with 6-week longitudinal cough characterization. Asia Pacific Allergy, 2022, 12, e19.	0.6	12
16	Clinical and transcriptomic features of persistent exacerbationâ€prone severe asthma in Uâ€BIOPRED cohort. Clinical and Translational Medicine, 2022, 12, e816.	1.7	11
17	Oxygen Desaturation Is Associated With Fibrocyte Activation via Epidermal Growth Factor Receptor/Hypoxia-Inducible Factor-1Î± Axis in Chronic Obstructive Pulmonary Disease. Frontiers in Immunology, 2022, 13, .	2.2	2
18	Chronic cough in asthma is associated with increased airway inflammation, more comorbidities, and worse clinical outcomes. Allergy and Asthma Proceedings, 2022, 43, 209-219.	1.0	6

#	Article	IF	Citations
19	Characteristics, phenotypes, mechanisms and management of severe asthma. Chinese Medical Journal, 2022, 135, 1141-1155.	0.9	12
20	Pathways linked to unresolved inflammation and airway remodelling characterize the transcriptome in two independent severe asthma cohorts. Respirology, 2022, 27, 730-738.	1.3	3
21	Cough hypersensitivity and chronic cough. Nature Reviews Disease Primers, 2022, 8, .	18.1	80
22	Clinical Assessment and Utility of Biomarkers in Asthma-Chronic Obstructive Pulmonary Disease Overlap. Immunology and Allergy Clinics of North America, 2022, , .	0.7	0
23	Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months. Journal of Allergy and Clinical Immunology, 2021, 147, 123-134.	1.5	51
24	Immune modulation via T regulatory cell enhancement: Diseaseâ€modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseasesâ€"An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 90-113.	2.7	24
25	Sputum macrophage diversity and activation in asthma: Role of severity and inflammatory phenotype. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 775-788.	2.7	25
26	Urinary Leukotriene E₄and Prostaglandin D₂Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 37-53.	2.5	49
27	Instability of sputum molecular phenotypes in U-BIOPRED severe asthma. European Respiratory Journal, 2021, 57, 2001836.	3.1	13
28	An overview of methods of fine and ultrafine particle collection for physicochemical characterisation and toxicity assessments. Science of the Total Environment, 2021, 756, 143553.	3.9	47
29	Type 2â€low asthma phenotypes by integration of sputum transcriptomics and serum proteomics. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 380-383.	2.7	20
30	Impact of Annual Exposure to Polycyclic Aromatic Hydrocarbons on Acute Exacerbation Frequency in Asthmatic Patients. Journal of Asthma and Allergy, 2021, Volume 14, 81-90.	1.5	4
31	Association of endopeptidases, involved in SARSâ€CoVâ€2 infection, with microbial aggravation in sputum of severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1917-1921.	2.7	3
32	Genome-Wide Association Study of Korean Asthmatics: A Comparison With UK Asthmatics. Allergy, Asthma and Immunology Research, 2021, 13, 609.	1.1	4
33	Chronic lung inflammation and pulmonary fibrosis after multiple intranasal instillation of <scp>PM₂</scp>_{.5} in mice. Environmental Toxicology, 2021, 36, 1434-1446.	2.1	31
34	More Data on Risks and Outcomes of COVID-19 in Asthma, COPD, and Bronchiectasis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2656-2657.	2.0	6
35	Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respiratory Medicine,the, 2021, 9, 533-544.	5.2	190
36	Increased Th1 Cells with Disease Resolution of Active Pulmonary Tuberculosis in Non-Atopic Patients. Biomedicines, 2021, 9, 724.	1.4	5

#	Article	IF	Citations
37	Editorial: Ozone as a Driver of Lung Inflammation and Innate Immunity and as a Model for Lung Disease. Frontiers in Immunology, 2021, 12, 714161.	2.2	8
38	Retrospective comparison of high-resolution computed tomography of eosinophilic granulomatosis with polyangiitis with severe asthma. Annals of Translational Medicine, 2021, 9, 983-983.	0.7	8
39	Altered gut microbiome compositions are associated with the severity of asthma. Journal of Thoracic Disease, 2021, 13, 4322-4338.	0.6	21
40	Urinary Amino-Polycyclic Aromatic Hydrocarbons in Urban Residents: Finding a Biomarker for Residential Exposure to Diesel Traffic. Environmental Science & Technology, 2021, 55, 10569-10577.	4.6	9
41	Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort. Chest, 2021, 160, 53-64.	0.4	10
42	Benefits of Airway Androgen Receptor Expression in Human Asthma. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 285-293.	2.5	26
43	Abnormal ADAM17 expression causes airway fibrosis in chronic obstructive asthma. Biomedicine and Pharmacotherapy, 2021, 140, 111701.	2.5	16
44	Nonâ€asthmatic eosinophilic bronchitis is characterized by proximal airway eosinophilic inflammation as compared with classic asthma and cough variant asthma. Clinical and Experimental Allergy, 2021, 51, 1637-1640.	1.4	2
45	Association Between Air Pollution and Lung Lobar Emphysema in COPD. Frontiers in Medicine, 2021, 8, 705792.	1.2	3
46	Increasing utility of FeNO as a biomarker of type-2 inflammation in severe asthma. Lancet Respiratory Medicine,the, 2021, 9, 1083-1084.	5.2	10
47	Upper Airways: Assessment and Treatment for Cough. , 2021, , 29-36.		0
48	Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma. Respiratory Research, 2021, 22, 10.	1.4	27
49	Patients' experiences of asthma exacerbation and management: a qualitative study of severe asthma. ERJ Open Research, 2021, 7, 00528-2020.	1.1	15
50	Interstitial lung abnormalities: What do we know and how do we manage?. Expert Review of Respiratory Medicine, 2021, 15, 1551-1561.	1.0	0
51	3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. European Respiratory Journal, 2021, 58, 2102168.	3.1	8
52	Emphysema-Predominant COPD Had a Greater 5-Year Mortality and a Worse Annual Decline in Lung Function Than Airway Obstruction-Predominant COPD or Asthma at Initial Same Degree of Airflow Obstruction. Medicina (Lithuania), 2021, 57, 1261.	0.8	0
53	Influence of Comorbidities and Airway Clearance on Mortality and Outcomes of Patients With Severe Bronchiectasis Exacerbations in Taiwan. Frontiers in Medicine, 2021, 8, 812775.	1.2	10
54	Clinical and Inflammatory Characteristics of the Chinese APAC Cough Variant Asthma Cohort. Frontiers in Medicine, 2021, 8, 807385.	1.2	5

#	Article	IF	Citations
55	Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 2020, 55, 1900588.	3.1	380
56	Relationships between airborne pollutants, serum albumin adducts and short-term health outcomes in an experimental crossover study. Chemosphere, 2020, 239, 124667.	4.2	6
57	Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 370-380.	2.7	37
58	Exploring the clinical relevance of cough hypersensitivity syndrome. Expert Review of Respiratory Medicine, 2020, 14, 275-284.	1.0	12
59	Accounting for measurement error to assess the effect of air pollution on omic signals. PLoS ONE, 2020, 15, e0226102.	1.1	4
60	Role of Metabolic Reprogramming in Pulmonary Innate Immunity and Its Impact on Lung Diseases. Journal of Innate Immunity, 2020, 12, 31-46.	1.8	58
61	Asthma similarities across ProAR (Brazil) and U-BIOPRED (Europe) adult cohorts of contrasting locations, ethnicity and socioeconomic status. Respiratory Medicine, 2020, 161, 105817.	1.3	13
62	Mitochondrial dysfunction in airways and quadriceps muscle of patients with chronic obstructive pulmonary disease. Respiratory Research, 2020, 21, 262.	1.4	27
63	Oxidative Stress in Ozone-Induced Chronic Lung Inflammation and Emphysema: A Facet of Chronic Obstructive Pulmonary Disease. Frontiers in Immunology, 2020, 11, 1957.	2.2	108
64	eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy. Journal of Allergy and Clinical Immunology, 2020, 146, 1045-1055.	1.5	22
65	Pathophysiological regulation of lung function by the free fatty acid receptor FFA4. Science Translational Medicine, 2020, 12, .	5.8	20
66	HSD3B1 genotype identifies glucocorticoid responsiveness in severe asthma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2187-2193.	3.3	27
67	Respiratory Viral Infections in Exacerbation of Chronic Airway Inflammatory Diseases: Novel Mechanisms and Insights From the Upper Airway Epithelium. Frontiers in Cell and Developmental Biology, 2020, 8, 99.	1.8	37
68	Effectiveness of myAirCoach: A mHealth Self-Management System in Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1972-1979.e8.	2.0	42
69	Vitamin D Metabolism Is Dysregulated in Asthma and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 371-382.	2.5	56
70	Toward personalization of asthma treatment according to trigger factors. Journal of Allergy and Clinical Immunology, 2020, 145, 1529-1534.	1.5	30
71	Pharmacotherapeutic Options for Chronic Refractory Cough. Expert Opinion on Pharmacotherapy, 2020, 21, 1345-1358.	0.9	17
72	Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. European Respiratory Journal, 2020, 55, 1902056.	3.1	84

#	Article	IF	Citations
73	Effect of silver nanospheres and nanowires on human airway smooth muscle cells: role of sulfidation. Nanoscale Advances, 2020, 2, 5635-5647.	2.2	7
74	Characteristics and treatment regimens across ERS SHARP severe asthma registries. European Respiratory Journal, 2020, 55, 1901163.	3.1	56
75	TLR3/TAK1 signalling regulates rhinovirus-induced interleukin-33 in bronchial smooth muscle cells. ERJ Open Research, 2020, 6, 00147-2020.	1.1	5
76	Early radiologic and bronchoscopic changes after bronchial thermoplasty in patients with severe asthma. Experimental and Therapeutic Medicine, 2020, 20, 278.	0.8	0
77	Early radiologic and bronchoscopic changes after bronchial thermoplasty in patients with severe asthma. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	0
78	Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. Journal of Allergy and Clinical Immunology, 2019, 143, 577-590.	1.5	140
79	Label-Free Time-of-Flight Secondary Ion Mass Spectrometry Imaging of Sulfur-Producing Enzymes inside Microglia Cells following Exposure to Silver Nanowires. Analytical Chemistry, 2019, 91, 11098-11107.	3.2	9
80	Blood eosinophil count correlates with severity of respiratory failure in lifeâ€threatening asthma and predicts risk of subsequent exacerbations. Clinical and Experimental Allergy, 2019, 49, 1578-1586.	1.4	16
81	TRPV1 and TRPA1 in Lung Inflammation and Airway Hyperresponsiveness Induced by Fine Particulate Matter (PM_{2.5}). Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-15.	1.9	48
82	Transcriptional Effects of Ozone and Impact on Airway Inflammation. Frontiers in Immunology, 2019, 10, 1610.	2.2	52
83	Acute Respiratory Barrier Disruption by Ozone Exposure in Mice. Frontiers in Immunology, 2019, 10, 2169.	2.2	55
84	ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. European Respiratory Journal, 2019, 54, 1900900.	3.1	56
85	Asthma phenotypes in a multi-ethnic Asian cohort. Respiratory Medicine, 2019, 157, 42-48.	1.3	9
86	Progress in cough hypersensitivity at the Tenth London International Cough Symposium 2018 (10th) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.1	1
87	Contribution of airway eosinophils in airway wall remodeling in asthma: Role of <scp>MMP</scp>â€10 and <scp>MET</scp>. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1102-1112.	2.7	32
88	Stratification of asthma phenotypes by airway proteomic signatures. Journal of Allergy and Clinical Immunology, 2019, 144, 70-82.	1.5	59
89	Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet, The, 2019, 394, 407-418.	6.3	377
90	Heterogeneity of cough hypersensitivity mediated by TRPV1 and TRPA1 in patients with chronic refractory cough. Respiratory Research, 2019, 20, 112.	1.4	47

#	Article	IF	Citations
91	New understanding in the treatment of cough (NEUROCOUGH) ERS Clinical Research Collaboration: improving care and treatment for patients with cough. European Respiratory Journal, 2019, 53, 1900787.	3.1	12
92	Mitochondrial ROS and NLRP3 inflammasome in acute ozone-induced murine model of airway inflammation and bronchial hyperresponsiveness. Free Radical Research, 2019, 53, 780-790.	1.5	55
93	IL-17â€“high asthma with features of a psoriasis immunophenotype. Journal of Allergy and Clinical Immunology, 2019, 144, 1198-1213.	1.5	80
94	Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation. BioMed Research International, 2019, 2019, 1-11.	0.9	23
95	Functional effects of the microbiota in chronic respiratory disease. Lancet Respiratory Medicine,the, 2019, 7, 907-920.	5.2	269
96	Health effects of air pollution: what we need to know and to do in the next decade. Journal of Thoracic Disease, 2019, 11, 1727-1730.	0.6	13
97	Maintenance Negative Pressure Ventilation Improves Survival in COPD Patients with Exercise Desaturation. Journal of Clinical Medicine, 2019, 8, 562.	1.0	3
98	Epithelial dysregulation in obese severe asthmatics with gastro-oesophageal reflux. European Respiratory Journal, 2019, 53, 1900453.	3.1	15
99	Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1649-1659.	2.7	75
100	Predicting Response to Triamcinolone in Severe Asthma by Machine Learning. Solving the Enigma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1299-1300.	2.5	2
101	Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. Lancet Respiratory Medicine,the, 2019, 7, 20-34.	5.2	183
102	â€œT2-highâ€•in severe asthma related to blood eosinophil, exhaled nitric oxide andÂserum periostin. European Respiratory Journal, 2019, 53, 1800938.	3.1	104
103	CSF3R/CD114 mediates infection-dependent transition to severe asthma. Journal of Allergy and Clinical Immunology, 2019, 143, 785-788.e6.	1.5	28
104	2-year safety and efficacy results for benralizumab. Lancet Respiratory Medicine,the, 2019, 7, 5-6.	5.2	3
105	Protective effects of VGX-1027 in PM2.5-induced airway inflammation and bronchial hyperresponsiveness. European Journal of Pharmacology, 2019, 842, 373-383.	1.7	19
106	Shedding light on corticosteroid-resistant type 2â€“high severe asthma. Journal of Allergy and Clinical Immunology, 2019, 143, 89-90.	1.5	4
107	Identification and prospective stability of electronic nose (eNose)â€“derived inflammatory phenotypes in patients with severe asthma. Journal of Allergy and Clinical Immunology, 2019, 143, 1811-1820.e7.	1.5	74
108	Roles of TRPA1 and TRPV1 in cigarette smoke -induced airway epithelial cell injury model. Free Radical Biology and Medicine, 2019, 134, 229-238.	1.3	103

#	Article	IF	Citations
109	Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An <scp>EAACI</scp> Taskforce on Immunopharmacology position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 432-448.	2.7	37
110	Impact of short-term traffic-related air pollution on the metabolome â€“ Results from two metabolome-wide experimental studies. Environment International, 2019, 123, 124-131.	4.8	42
111	Treatable traits in the European Uâ€<scp>BIOPRED</scp> adult asthma cohorts. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 406-411.	2.7	37
112	Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma?. , 2019, , .		1
113	Characteristics and treatment regimens across ERS SHARP severe asthma registries. , 2019, , .		3
114	myAirCoach: mHealth assisted self-management in patients with uncontrolled asthma, a randomized control trial. , 2019, , .		1
115	Future Risks in Patients With Severe Asthma. Allergy, Asthma and Immunology Research, 2019, 11, 763.	1.1	43
116	Age and Sex Distribution of Chinese Chronic Cough Patients and Their Relationship With Capsaicin Cough Sensitivity. Allergy, Asthma and Immunology Research, 2019, 11, 871.	1.1	30
117	The lung microbiome in obstructive airways disease: potential pathogenetic roles. , 2019, , 140-157.		0
118	Molecular phenotypes of severe asthma. , 2019, , 184-194.		0
119	Corticosteroid responsiveness and resistance in severe asthma. , 2019, , 211-230.		1
120	Severe asthma: the next decade of continuing progress. , 2019, , 327-333.		0
121	Severe asthma management in adults. , 2019, , 315-326.		0
122	Subtypes of eosinophilic asthma with discrete gene pathway phenotypes. , 2019, , .		0
123	Differential macrophage activation in asthmatic sputum using U-BIOPRED transcriptomics. , 2019, , .		0
124	Regulation of mitochondrial transfer between airway smooth muscle cells: relevance to COPD. , 2019, , .		0
125	Oxygen desaturation is associated with fibrocyte activation via epidermal growth factor receptor/hypoxia-inducible factor(HIF)-1a axis in COPD. , 2019, , .		1
126	Sputum gene signature comparison study between U-BIOPRED and Australia asthma cohorts. , 2019, , .		0

#	Article	IF	Citations
127	Altered mitochondrial reactive oxygen species (ROS) production in airway smooth muscle cells of severe asthma. , 2019, , .		0
128	Altered mitochondrial function in proliferating airway smooth muscle cells. , 2019, , .		0
129	Green respiratory health care: Time for us all to act. Respirology, 2018, 23, 452-454.	1.3	1
130	Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. European Respiratory Journal, 2018, 51, 1702173.	3.1	67
131	DNA methylation modules in airway smooth muscle are associated with asthma severity. European Respiratory Journal, 2018, 51, 1701068.	3.1	25
132	The human circulating miRNome reflects multiple organ disease risks in association with short-term exposure to traffic-related air pollution. Environment International, 2018, 113, 26-34.	4.8	60
133	Diagnosis and Management of Severe Asthma. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 091-099.	0.8	23
134	Cys34 Adductomes Differ between Patients with Chronic Lung or Heart Disease and Healthy Controls in Central London. Environmental Science & Technology, 2018, 52, 2307-2313.	4.6	29
135	Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nature Genetics, 2018, 50, 42-53.	9.4	426
136	TGF-Î² Signaling Pathways in Different Compartments of the Lower Airways of Patients With Stable COPD. Chest, 2018, 153, 851-862.	0.4	43
137	Exacerbations in Adults with Asthma: A Systematic Review and External Validation of Prediction Models. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1942-1952.e15.	2.0	49
138	Asthma Phenotypes Defined From Parameters Obtained During Recovery From a Hospital-Treated Exacerbation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1960-1967.	2.0	22
139	Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. Journal of Allergy and Clinical Immunology, 2018, 141, 560-570.	1.5	166
140	Precision medicine in asthma. Current Opinion in Pulmonary Medicine, 2018, 24, 4-10.	1.2	61
141	Mesenchymal stem cells alleviate oxidative stressâ€“induced mitochondrial dysfunction in the airways. Journal of Allergy and Clinical Immunology, 2018, 141, 1634-1645.e5.	1.5	103
142	Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, crossover study. Lancet, The, 2018, 391, 339-349.	6.3	294
143	Pathway discovery using transcriptomic profiles in adult-onset severe asthma. Journal of Allergy and Clinical Immunology, 2018, 141, 1280-1290.	1.5	105
144	Roles of mitochondrial ROS and NLRP3 inflammasome in multiple ozone-induced lung inflammation and emphysema. Respiratory Research, 2018, 19, 230.	1.4	77

#	Article	IF	Citations
145	Respiratory disease mortality in the United Kingdom compared with EU15+ countries in 1985-2015: observational study. BMJ: British Medical Journal, 2018, 363, k4680.	2.4	31
146	The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research. European Respiratory Journal, 2018, 52, 1801671.	3.1	28
147	Lipid phenotyping of lung epithelial lining fluid in healthy human volunteers. Metabolomics, 2018, 14, 123.	1.4	17
148	Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort. PLoS ONE, 2018, 13, e0203874.	1.1	18
149	Relationship between free and total malondialdehyde, a well-established marker of oxidative stress, in various types of human biospecimens. Journal of Thoracic Disease, 2018, 10, 3088-3197.	0.6	65
150	IFN-Î³: A Driver of Cough Hypersensitivity Pathways in Chronic Cough?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 827-828.	2.5	2
151	International research collaboration: The way forward. Respirology, 2018, 23, 654-655.	1.3	4
152	Tralokinumab unsuccessful for management of severe, uncontrolled asthma. Lancet Respiratory Medicine,the, 2018, 6, 480-481.	5.2	13
153	AsthmaMap: An expertâ€driven computational representation of disease mechanisms. Clinical and Experimental Allergy, 2018, 48, 916-918.	1.4	21
154	Exposure to Silver Nanospheres Leads to Altered Respiratory Mechanics and Delayed Immune Response in an in Vivo Murine Model. Frontiers in Pharmacology, 2018, 9, 213.	1.6	14
155	Discovery and Validation of New Biomarkers for Personalizing Asthma Therapy. , 2018, , 87-95.		1
156	A computational framework for complex disease stratification from multiple large-scale datasets. BMC Systems Biology, 2018, 12, 60.	3.0	43
157	Interleukin-1Î± Mediates Ozone-Induced Myeloid Differentiation Factor-88-Dependent Epithelial Tissue Injury and Inflammation. Frontiers in Immunology, 2018, 9, 916.	2.2	25
158	The small airway epithelium as a target for the adverse pulmonary effects of silver nanoparticle inhalation. Nanotoxicology, 2018, 12, 539-553.	1.6	24
159	The anti-proliferative and anti-inflammatory response of COPD airway smooth muscle cells to hydrogen sulfide. Respiratory Research, 2018, 19, 85.	1.4	20
160	Large-Scale Label-Free Quantitative Mapping of the Sputum Proteome. Journal of Proteome Research, 2018, 17, 2072-2091.	1.8	16
161	Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials. Journal of Thoracic Disease, 2018, 10, 1084-1098.	0.6	45
162	Increased matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio in smokers with airway hyperresponsiveness and accelerated lung function decline. International Journal of COPD, 2018, Volume 13, 1135-1144.	0.9	15

#	Article	IF	Citations
163	The heterogeneity of chronic cough: a case for endotypes of cough hypersensitivity. Lancet Respiratory Medicine,the, 2018, 6, 636-646.	5.2	64
164	U-BIOPRED accessible handprint: combining omics platforms to identify stable asthma subphenotypes. , 2018, , .		2
165	Topological data analysis (TDA) of U-BIOPRED paediatric peripheral blood gene expression identified asthma phenotypes characterised by alternative splicing of glucocorticoid receptor (GR) mRNA. , 2018, , .		2
166	Advancing the Understanding of Environmental Transformations, Bioavailability and Effects of Nanomaterials, an International US Environmental Protection Agencyâ€"UK Environmental Nanoscience Initiative Joint Program. Journal of Environmental Protection, 2018, 09, 385-404.	0.3	5
167	Cough Hypersensitivity Syndrome â€“ A Major Advance in the Understanding of Chronic Cough. European Respiratory & Pulmonary Diseases, 2018, 4, 19.	0.2	0
168	Gastro-Oesophageal Reflux Disease (GORD) and Chronic Cough. , 2018, , 205-212.		0
169	Late Breaking Abstract - Longitudinal analysis of variation in clinical features from the U-BIOPRED severe asthma cohort. , 2018, , .		0
170	MIF antagonism restores corticosteroid sensitivity in a murine model of severe asthma. , 2018, , .		0
171	Unsupervised and externally validated clinical cluster analysis from the U-BIOPRED paediatric cohorts. , 2018, , .		0
172	Clinical and transcriptomic profiles of severe asthmatics with high or low expression of the glucocorticoid receptor and importin-7.. , 2018, , .		0
173	Transcriptional profiling identifies the long noncoding RNA plasmacytoma variant translocation () Tj ETQq1 1 0.784314 rgBT /Overloc Allergy and Clinical Immunology, 2017, 139, 780-789.	1.5	95
174	Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax, 2017, 72, 129-136.	2.7	130
175	Advances in mechanisms and management of chronic cough: The Ninth London International Cough Symposium 2016. Pulmonary Pharmacology and Therapeutics, 2017, 47, 2-8.	1.1	20
176	Inactivation, Clearance, and Functional Effects of Lung-Instilled Short and Long Silver Nanowires in Rats. ACS Nano, 2017, 11, 2652-2664.	7.3	30
177	Release of airborne particles and Ag and Zn compounds from nanotechnology-enabled consumer sprays: Implications for inhalation exposure. Atmospheric Environment, 2017, 155, 85-96.	1.9	21
178	MyAirCoach: the use of home-monitoring and mHealth systems to predict deterioration in asthma control and the occurrence of asthma exacerbations; study protocol of an observational study. BMJ Open, 2017, 7, e013935.	0.8	51
179	T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. European Respiratory Journal, 2017, 49, 1602135.	3.1	283
180	Silver nanoparticles reduce brain inflammation and related neurotoxicity through induction of H2S-synthesizing enzymes. Scientific Reports, 2017, 7, 42871.	1.6	110

#	Article	IF	Citations
181	Analysis of bronchial biopsies in chronic cough. Respiratory Medicine, 2017, 127, 40-44.	1.3	12
182	The â€œIronâ€•y of Iron Overload and Iron Deficiency in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1103-1112.	2.5	76
183	Perspectives of patients and healthcare professionals on mHealth for asthma self-management. European Respiratory Journal, 2017, 49, 1601966.	3.1	61
184	Addressing unmet needs in understanding asthma mechanisms. European Respiratory Journal, 2017, 49, 1602448.	3.1	47
185	Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression. European Respiratory Journal, 2017, 49, 1602006.	3.1	63
186	Airway microbial dysbiosis in asthmatic patients: AÂtarget for prevention and treatment?. Journal of Allergy and Clinical Immunology, 2017, 139, 1071-1081.	1.5	124
187	Clinical management of severe therapy-resistant asthma. Expert Review of Respiratory Medicine, 2017, 11, 1-8.	1.0	17
188	Allergic airway inflammation induces migration of mast cell populations into the mouse airway. Cell and Tissue Research, 2017, 369, 331-340.	1.5	11
189	A Severe Asthma Disease Signature from Gene Expression Profiling of Peripheral Blood from U-BIOPRED Cohorts. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1311-1320.	2.5	152
190	Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2017, 11, 955-967.	1.0	0
191	Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma. European Respiratory Journal, 2017, 50, 1602298.	3.1	44
192	Personalised medicine in asthma: time for action. European Respiratory Review, 2017, 26, 170064.	3.0	32
193	Sputum microbiota in severe asthma patients: Relationship to eosinophilic inflammation. Respiratory Medicine, 2017, 131, 192-198.	1.3	83
194	Impaired innate immune gene profiling in airway smooth muscle cells from chronic cough patients. Bioscience Reports, 2017, 37, .	1.1	9
195	The Objective Assessment of Cough Frequency in Bronchiectasis. Lung, 2017, 195, 575-585.	1.4	18
196	Assessing machine learning algorithms for self-management of asthma. , 2017, , .		9
197	Metabolic re-patterning in COPD airway smooth muscle cells. European Respiratory Journal, 2017, 50, 1700202.	3.1	48
198	The Ninth 2016 International London Cough Symposium. Pulmonary Pharmacology and Therapeutics, 2017, 47, 1.	1.1	5

#	Article	IF	Citations
199	Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma?. European Respiratory Review, 2017, 26, 170040.	3.0	37
200	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. Journal of Allergy and Clinical Immunology, 2017, 139, 1797-1807.	1.5	236
201	Imbalance of endogenous prostanoids in moderate-to-severe asthma. Allergology International, 2017, 66, 83-88.	1.4	8
202	A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 443-455.	2.5	165
203	Reduced suppressive effect of Î²2-adrenoceptor agonist on fibrocyte function in severe asthma. Respiratory Research, 2017, 18, 194.	1.4	3
204	Proteomic analysis of sputum reveals novel biomarkers for various presentations of asthma. Journal of Translational Medicine, 2017, 15, 171.	1.8	20
205	Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle. International Journal of COPD, 2017, Volume 12, 1903-1913.	0.9	2
206	Theobromine for the treatment of persistent cough: a randomised, multicentre, double-blind, placebo-controlled clinical trial. Journal of Thoracic Disease, 2017, 9, 1864-1872.	0.6	8
207	Volatile Organic Compounds Breathprinting of U-BIOPRED Severe Asthma smokers/ex-smokers cohort. , 2017, , .		2
208	Potential Role of the Lung Microbiome in Shaping Asthma Phenotypes. Annals of the American Thoracic Society, 2017, 14, S326-S331.	1.5	31
209	Dealing with Stress: Defective Metabolic Adaptation in Chronic Obstructive Pulmonary Disease Pathogenesis. Annals of the American Thoracic Society, 2017, 14, S374-S382.	1.5	14
210	Late Breaking Abstract - Comparison of clinical characteristics between severe adult asthmatics in Brazil(ProAR) and Europe(U-BIOPRED). , 2017, , .		2
211	Gene signatures from U-BIOPRED transcriptomic-associated clusters exist in COPD. , 2017, , .		0
212	Late Breaking Abstract - Cluster analysis of treatable traits in the U-BIOPRED adult severe asthma cohort. , 2017, , .		0
213	TGF-Î²1-Mediated CTGF Upregulation Through Transactivation of EGFR in Fibrocytes of Chronic Obstructive Asthma. , 2017, , .		0
214	A hypothesis driven approach investigating the interleukin-6 pathway in UBIOPRED severe asthma patients. , 2017, , .		0
215	Bromodomain And Extra-Terminal (BET) proteins regulate metabolic and redox function in COPD airway smooth muscle cells. , 2017, , .		0
216	Low-dose AgNPs reduce lung mechanical function and innate immune defense in the absence of cellular toxicity. Nanotoxicology, 2016, 10, 1-10.	1.6	23

#	Article	IF	Citations
217	Pulmonary effects of inhalation of spark-generated silver nanoparticles in Brown-Norway and Sprague–Dawley rats. Respiratory Research, 2016, 17, 85.	1.4	42
218	Airway smooth muscle inflammation is regulated by micro<scp>RNA</scp>–145 in <scp>COPD</scp>. FEBS Letters, 2016, 590, 1324-1334.	1.3	62
219	Nasal inflammation and its response to local glucocorticoid regular treatment in patients with persistent non-allergic rhinitis: a pilot study. Journal of Inflammation, 2016, 13, 26.	1.5	2
220	Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model. Thorax, 2016, 71, 838-846.	2.7	74
221	Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respiratory Research, 2016, 17, 165.	1.4	107
222	Pulmonary surfactant mitigates silver nanoparticle toxicity in human alveolar type-I-like epithelial cells. Colloids and Surfaces B: Biointerfaces, 2016, 145, 167-175.	2.5	30
223	Exercise-Induced Changes in Exhaled NO Differentiates Asthma With or Without Fixed Airway Obstruction From COPD With Dynamic Hyperinflation. Medicine (United States), 2016, 95, e3400.	0.4	8
224	Corticosteroid modulation of immunoglobulin expression and B–cell function in COPD. FASEB Journal, 2016, 30, 2014-2026.	0.2	29
225	Dupilumab: a potential new treatment for severe asthma. Lancet, The, 2016, 388, 3-4.	6.3	17
226	Neutrophilic asthma: a distinct target for treatment?. Lancet Respiratory Medicine,the, 2016, 4, 765-767.	5.2	27
227	Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action. Lancet, The, 2016, 388, 1939-1951.	6.3	649
228	Carboxylation of multiwalled carbon nanotubes reduces their toxicity in primary human alveolar macrophages. Environmental Science: Nano, 2016, 3, 1340-1350.	2.2	26
229	Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. Journal of Internal Medicine, 2016, 279, 192-204.	2.7	130
230	Chronic cough and cough hypersensitivity syndrome. Lancet Respiratory Medicine,the, 2016, 4, 934-935.	5.2	31
231	Effects of a nanoceria fuel additive on the physicochemical properties of diesel exhaust particles. Environmental Sciences: Processes and Impacts, 2016, 18, 1333-1342.	1.7	11
232	Effect of pulmonary surfactant on the dissolution, stability and uptake of zinc oxide nanowires by human respiratory epithelial cells. Nanotoxicology, 2016, 10, 1351-1362.	1.6	42
233	Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study. European Respiratory Journal, 2016, 48, 1307-1319.	3.1	44
234	Mapping physiological G protein-coupled receptor signaling pathways reveals a role for receptor phosphorylation in airway contraction. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4524-4529.	3.3	46

#	Article	IF	Citations
235	Decreased breath excretion of redox active iron in COPD: a protective failure?. European Respiratory Journal, 2016, 47, 1267-1270.	3.1	12
236	Staphylococcal enterotoxinâ€specific IgE: a biomarker for a distinct phenotype of severe asthma?. Clinical and Experimental Allergy, 2016, 46, 387-389.	1.4	5
237	Chronic exposure to air pollution particles increases the risk of obesity and metabolic syndrome: findings from a natural experiment in Beijing. FASEB Journal, 2016, 30, 2115-2122.	0.2	181
238	Hydrogen Sulfide Prevents and Partially Reverses Ozone-Induced Features of Lung Inflammation and Emphysema in Mice. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 72-81.	1.4	36
239	Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Translational Research, 2016, 167, 192-203.	2.2	100
240	Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax, 2016, 71, 187-189.	2.7	78
241	The MIF Antagonist ISO-1 Attenuates Corticosteroid-Insensitive Inflammation and Airways Hyperresponsiveness in an Ozone-Induced Model of COPD. PLoS ONE, 2016, 11, e0146102.	1.1	43
242	Airway Microbiota in Severe Asthma and Relationship to Asthma Severity and Phenotypes. PLoS ONE, 2016, 11, e0152724.	1.1	159
243	mHealth systems for asthma self-management: Opinions of people with asthma and healthcare professionals (HCPs) on their use and functions. , 2016, , .		0
244	Breathing pattern changes in refractory chronic cough with physiotherapy speech and language therapy intervention. , 2016, , .		0
245	Patients' perspective of physiotherapy, speech and language therapy intervention (PSALTI) for refractory chronic cough:Secondary analysis. , 2016, , .		0
246	Lipid biomarkers predictive of gastro-oesophageal reflux in adult asthma. , 2016, , .		0
247	Proteome fingerprints define groups with distinct clinico-pathological phenotypes in the U-BIOPRED asthma study. , 2016, , .		0
248	Rhinovirus-induced IL-33 expression in asthmatic airway smooth muscle cells is TLR3-dependent and involves activation of TAK1. , 2016, , .		0
249	Glycogen synthase kinase-3Î² modulation of glucocorticoid responsiveness in COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L1112-L1123.	1.3	21
250	Physician-prescribed Asthma Treatment Regimen does not differ Between Smoking and Non-smoking Patients With Asthma in Seoul and Gyunggi province of Korea. Allergy, Asthma and Immunology Research, 2015, 7, 30.	1.1	1
251	Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD. International Journal of COPD, 2015, 10, 283.	0.9	26
252	Indications for the use of bronchial thermoplasty in severe asthma. South African Medical Journal, 2015, 105, 808.	0.2	0

#	Article	IF	Citations
253	Modeling In Vivo Interactions of Engineered Nanoparticles in the Pulmonary Alveolar Lining Fluid. Nanomaterials, 2015, 5, 1223-1249.	1.9	6
254	Oxidants Induce a Corticosteroid-Insensitive Phosphorylation of Histone 3 at Serine 10 in Monocytes. PLoS ONE, 2015, 10, e0124961.	1.1	13
255	Modulation of Human Macrophage Responses to Mycobacterium tuberculosis by Silver Nanoparticles of Different Size and Surface Modification. PLoS ONE, 2015, 10, e0143077.	1.1	43
256	Recommendations for the use of bronchial thermoplasty in the management of severe asthma. South African Medical Journal, 2015, 105, 726.	0.2	3
257	Silver nanowire interactions with primary human alveolar type-II epithelial cell secretions: contrasting bioreactivity with human alveolar type-I and type-II epithelial cells. Nanoscale, 2015, 7, 10398-10409.	2.8	31
258	A silent revolution: phenotyping asthma for personalised medicine. Revista Portuguesa De Pneumologia, 2015, 21, 293-294.	0.7	1
259	Adsorption of surfactant protein D from human respiratory secretions by carbon nanotubes and polystyrene nanoparticles depends on nanomaterial surface modification and size. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140038.	1.8	13
260	Inhibitory Effect of Hydrogen Sulfide on Ozone-Induced Airway Inflammation, Oxidative Stress, and Bronchial Hyperresponsiveness. American Journal of Respiratory Cell and Molecular Biology, 2015, 52, 129-137.	1.4	35
261	Increased phenotypic differentiation and reduced corticosteroid sensitivity of fibrocytes in severe asthma. Journal of Allergy and Clinical Immunology, 2015, 135, 1186-1195.e6.	1.5	36
262	Fibrocyte trafficking in patients with chronic obstructive asthma and during an acute asthma exacerbation. Journal of Allergy and Clinical Immunology, 2015, 135, 1154-1162.e5.	1.5	40
263	Static and Dynamic Microscopy of the Chemical Stability and Aggregation State of Silver Nanowires in Components of Murine Pulmonary Surfactant. Environmental Science & Technology, 2015, 49, 8048-8056.	4.6	21
264	Oxidative stressâ€“induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2015, 136, 769-780.	1.5	332
265	Tiotropium as an add-on therapy in patients with symptomatic asthma. Lancet Respiratory Medicine,the, 2015, 3, 331-333.	5.2	5
266	Phospho-p38 MAPK Expression in COPD Patients and Asthmatics and in Challenged Bronchial Epithelium. Respiration, 2015, 89, 329-342.	1.2	20
267	Cough hypersensitivity syndrome: clinical measurement is the key to progress. European Respiratory Journal, 2015, 45, 1509-1510.	3.1	25
268	Role of microRNAs in allergic asthma. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 156-162.	1.1	46
269	Managing severe asthma in adults. Current Opinion in Pulmonary Medicine, 2015, 21, 8-15.	1.2	24
270	NMDA and GABA receptors as potential targets in cough hypersensitivity syndrome. Current Opinion in Pharmacology, 2015, 22, 29-36.	1.7	34

#	Article	IF	Citations
271	Clinical phenotypes of asthma should link up with disease mechanisms. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 56-62.	1.1	26
272	Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. European Respiratory Journal, 2015, 46, 1308-1321.	3.1	434
273	The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. European Respiratory Journal, 2015, 46, 1322-1333.	3.1	179
274	BET Bromodomains Regulate Transforming Growth Factor-Î²-induced Proliferation and Cytokine Release in Asthmatic Airway Smooth Muscle. Journal of Biological Chemistry, 2015, 290, 9111-9121.	1.6	49
275	Targeting the interleukin pathway in the treatment of asthma. Lancet, The, 2015, 386, 1086-1096.	6.3	230
276	Eight International London Cough Symposium 2014: Cough hypersensitivity syndrome as the basis for chronic cough. Pulmonary Pharmacology and Therapeutics, 2015, 35, 76-80.	1.1	15
277	Evidence for neuropathic processes in chronic cough. Pulmonary Pharmacology and Therapeutics, 2015, 35, 100-104.	1.1	45
278	Impaired Nuclear Translocation of the Glucocorticoid Receptor in Corticosteroid-Insensitive Airway Smooth Muscle in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 54-62.	2.5	54
279	Mitochondrial reactive oxygen species and glycolysis in airway smooth muscle cell proliferation in COPD. , 2015, , .		1
280	Pulmonary Toxicity of Instilled Silver Nanoparticles: Influence of Size, Coating and Rat Strain. PLoS ONE, 2015, 10, e0119726.	1.1	94
281	Nitric Oxide Sustains IL-1Î² Expression in Human Dendritic Cells Enhancing Their Capacity to Induce IL-17â€“Producing T-Cells. PLoS ONE, 2015, 10, e0120134.	1.1	17
282	Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma. PLoS ONE, 2015, 10, e0145476.	1.1	49
283	Link between environmental air pollution and allergic asthma: East meets West. Journal of Thoracic Disease, 2015, 7, 14-22.	0.6	35
284	Mechanistic impact of outdoor air pollution on asthma and allergic diseases. Journal of Thoracic Disease, 2015, 7, 23-33.	0.6	104
285	The first U-BIOPRED sputum handprint of severe asthma. , 2015, , .		0
286	Mapping a mouse model of severe asthma to human asthma using gene set variation analysis. , 2015, , .		0
287	Sputum supernatant profiling reveals inflammasome-associated signatures in severe asthmatics in U-BIOPRED. , 2015, , .		0
288	MMP10andMETas predictive classifiers of bronchial eosinophilic asthma in UBIOPRED. , 2015, , .		0

#	Article	IF	Citations
289	Effects of hydrogen sulfide on ozone-induced features of chronic obstructive pulmonary disease. , 2015, , .		0
290	The first U-BIOPRED blood handprint of severe asthma. , 2015, , .		0
291	Sputum microbiota in Chinese adults with eosinophilic versus non-eosinophilic asthma. , 2015, , .		0
292	Breathomics can discriminate between anti IgE-treated and non-treated severe asthma adults. , 2015, , .		0
293	Haze, health and disease. Journal of Thoracic Disease, 2015, 7, 1-2.	0.6	67
294	ModelingIn VitroCellular Responses to Silver Nanoparticles. Journal of Toxicology, 2014, 2014, 1-13.	1.4	12
295	Lipoxins and Epoxyeicosatrienoic Acids. Potential for Inhibitors of Soluble Epoxide Hydrolase in Severe Asthma?. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 848-850.	2.5	3
296	Modeling population exposures to silver nanoparticles present in consumer products. Journal of Nanoparticle Research, 2014, 16, 1.	0.8	33
297	Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Medicine, 2014, 6, 82.	3.6	169
298	Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control. European Respiratory Journal, 2014, 43, 474-484.	3.1	37
299	Role of mitogen-activated protein kinase phosphatase-1 in corticosteroid insensitivity of chronic oxidant lung injury. European Journal of Pharmacology, 2014, 744, 108-114.	1.7	14
300	Abraham (â€œAbeâ€) Guz: a life devoted to breathing and breathlessness. European Respiratory Journal, 2014, 44, 1423-1425.	3.1	0
301	A comprehensive analysis of oxidative stress in the ozone-induced lung inflammation mouse model. Clinical Science, 2014, 126, 425-440.	1.8	63
302	Hydrogen sulfide as a potential biomarker of asthma. Expert Review of Respiratory Medicine, 2014, 8, 5-13.	1.0	36
303	Comment on: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal, 2014, 44, 267-268.	3.1	16
304	Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD. International Journal of COPD, 2014, 9, 249.	0.9	1
305	"International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma." Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek, Andrew Bush, Mario Castro, Peter J. Sterk, Ian M. Adcock, Eric D. Bateman, Elisabeth H. Bel, Eugene R. Bleecker, Louis-Philippe Boulet, Christopher Brightling, Pascal Chanez, Sven-Erik Dahlen, Ratko Djukanovic, Urs Frey, Mina Gaga, Peter Gibson, Qutayba Hamid, Nizar N. Jajour, Thais Mauad, Ronald L. Sorkness and W. Gerald Teague. Eur Respir J 2014; 43: 343-373., European Respiratory Journal, 2014, 43, 1216-1216.	3.1	9
306	Mobile-phone-based home exercise training program decreases systemic inflammation in COPD: a pilot study. BMC Pulmonary Medicine, 2014, 14, 142.	0.8	35

#	Article	IF	Citations
307	Lipid-laden bronchoalveolar macrophages in asthma and chronic cough. Respiratory Medicine, 2014, 108, 71-77.	1.3	29
308	Defining Phenotypes in Asthma: A Step Towards Personalized Medicine. Drugs, 2014, 74, 719-728.	4.9	67
309	International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal, 2014, 43, 343-373.	3.1	2,898
310	A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response. European Respiratory Journal, 2014, 44, 1149-1155.	3.1	202
311	International European Respiratory Society/American Thoracic Society guidelines on severe asthma. European Respiratory Journal, 2014, 44, 1378-1379.	3.1	33
312	Targeted omics and systems medicine: personalising care. Lancet Respiratory Medicine,the, 2014, 2, 785-787.	5.2	20
313	Sputum-to-serum hydrogen sulfide ratio in COPD. Thorax, 2014, 69, 903-909.	2.7	26
314	Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. European Respiratory Journal, 2014, 44, 1132-1148.	3.1	294
315	Impaired macrophage phagocytosis of bacteria in severe asthma. Respiratory Research, 2014, 15, 72.	1.4	85
316	Modeling physicochemical interactions affecting in vitro cellular dosimetry of engineered nanomaterials: application to nanosilver. Journal of Nanoparticle Research, 2014, 16, 2616.	0.8	21
317	Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax, 2014, 69, 516-524.	2.7	99
318	Role of non-coding RNAs in maintaining primary airway smooth muscle cells. Respiratory Research, 2014, 15, 58.	1.4	66
319	Impact of theophylline/corticosteroid combination therapy on sputum hydrogen sulfide levels in patients with COPD. European Respiratory Journal, 2014, 43, 1504-1506.	3.1	19
320	Bromodomain and Extraterminal Proteins Suppress NF-E2â€“Related Factor 2â€“Mediated Antioxidant Gene Expression. Journal of Immunology, 2014, 192, 4913-4920.	0.4	61
321	Characterization of factors associated with systemic corticosteroid use in severe asthma: Data from the Severe Asthma Research Program. Journal of Allergy and Clinical Immunology, 2014, 133, 915-918.	1.5	27
322	Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. Journal of Allergy and Clinical Immunology, 2014, 133, 1280-1288.	1.5	247
323	Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 2014, 44, 304-323.	3.1	154
324	Cytokine inhibition in the treatment of COPD. International Journal of COPD, 2014, 9, 397.	0.9	88

#	Article	IF	Citations
325	Variability in Bioreactivity Linked to Changes in Size and Zeta Potential of Diesel Exhaust Particles in Human Immune Cells. PLoS ONE, 2014, 9, e97304.	1.1	12
326	Biology of Monocytes and Macrophages. , 2014, , 292-301.		0
327	Glucocorticosteroids. , 2014, , 1578-1601.		0
328	Approach to chronic cough: the neuropathic basis for cough hypersensitivity syndrome. Journal of Thoracic Disease, 2014, 6, S699-707.	0.6	30
329	John Widdicombeâ€™s contribution to respiratory physiology and cough: reminiscences. Cough, 2013, 9, 6.	2.7	4
330	Sputum and serum hydrogen sulfide (H₂S) as novel biomarker of asthma. Clinical and Translational Allergy, 2013, 3, P3.	1.4	1
331	The Stability of Silver Nanoparticles in a Model of Pulmonary Surfactant. Environmental Science & Technology, 2013, 47, 11232-11240.	4.6	99
332	Sulfidation of silver nanowires inside human alveolar epithelial cells: a potential detoxification mechanism. Nanoscale, 2013, 5, 9839.	2.8	56
333	Impacts of a Nanosized Ceria Additive on Diesel Engine Emissions of Particulate and Gaseous Pollutants. Environmental Science & Technology, 2013, 47, 13077-13085.	4.6	63
334	Safety of bronchial thermoplasty in patients with severe refractory asthma. Annals of Allergy, Asthma and Immunology, 2013, 111, 402-407.	0.5	91
335	The Seventh International Symposium on Cough: Hypertussivity and allotussivity. Pulmonary Pharmacology and Therapeutics, 2013, 26, 475.	1.1	3
336	New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respiratory Medicine,the, 2013, 1, 639-652.	5.2	81
337	IL-22 suppresses IFN-Î³â€“mediated lung inflammation in asthmatic patients. Journal of Allergy and Clinical Immunology, 2013, 131, 562-570.	1.5	79
338	Tobacco industry lobbyists and their health-care clients. Lancet, The, 2013, 381, 445.	6.3	3
339	Regulation of Wnt4 in chronic obstructive pulmonary disease. FASEB Journal, 2013, 27, 2367-2381.	0.2	32
340	Chronic cough as a neuropathic disorder. Lancet Respiratory Medicine,the, 2013, 1, 414-422.	5.2	189
341	Effect of serum on diesel exhaust particles (DEP)-induced apoptosis of airway epithelial cells in vitro. Toxicology Letters, 2013, 218, 215-223.	0.4	14
342	Sputum hydrogen sulfide as a novel biomarker of obstructive neutrophilic asthma. Journal of Allergy and Clinical Immunology, 2013, 131, 232-234.e3.	1.5	46

#	Article	IF	Citations
343	Application of â€™omics technologies to biomarker discovery in inflammatory lung diseases. European Respiratory Journal, 2013, 42, 802-825.	3.1	234
344	High-Resolution Analytical Electron Microscopy Reveals Cell Culture Media-Induced Changes to the Chemistry of Silver Nanowires. Environmental Science & Technology, 2013, 47, 13813-13821.	4.6	33
345	An Association between <scp>l</scp>-Arginine/Asymmetric Dimethyl Arginine Balance, Obesity, and the Age of Asthma Onset Phenotype. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 153-159.	2.5	141
346	How Variability in Clinical Phenotypes Should Guide Research into Disease Mechanisms in Asthma. Annals of the American Thoracic Society, 2013, 10, S109-S117.	1.5	34
347	Airway Smooth Muscle Hyperproliferation is Regulated by microRNA-221 in Severe Asthma. American Journal of Respiratory Cell and Molecular Biology, 2013, 50, 130814131000002.	1.4	136
348	Activation of p38 mitogenâ€activated protein kinase in ovalbumin and ozoneâ€induced mouse model of asthma. Respirology, 2013, 18, 20-29.	1.3	26
349	A Polymorphism Affecting<scp>MYB</scp>Binding within the Promoter of thePDCD4Gene is Associated with Severe Asthma in Children. Human Mutation, 2013, 34, 1131-1139.	1.1	24
350	Obesity-Associated Severe Asthma Represents a Distinct Clinical Phenotype. Chest, 2013, 143, 406-414.	0.4	109
351	Characteristics of Perimenstrual Asthma and Its Relation to Asthma Severity and Control. Chest, 2013, 143, 984-992.	0.4	78
352	IL-17A Modulates Oxidant Stress-Induced Airway Hyperresponsiveness but Not Emphysema. PLoS ONE, 2013, 8, e58452.	1.1	33
353	Effects of N-Acetylcysteine in Ozone-Induced Chronic Obstructive Pulmonary Disease Model. PLoS ONE, 2013, 8, e80782.	1.1	40
354	Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease. Current Medicinal Chemistry, 2013, 20, 4317-4349.	1.2	19
355	Inflammatory biomarkers in severe asthma. Current Opinion in Pulmonary Medicine, 2012, 18, 35-41.	1.2	27
356	Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 356-362.	2.5	242
357	Oxidative Stressâ€“induced Antibodies to Carbonyl-modified Protein Correlate with Severity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1026-1027.	2.5	3
358	How to Diagnose and Phenotype Asthma. Clinics in Chest Medicine, 2012, 33, 445-457.	0.8	42
359	Sleep quality and asthma control and quality of life in non-severe and severe asthma. Sleep and Breathing, 2012, 16, 1129-1137.	0.9	89
360	Gabapentin: a suppressant for refractory chronic cough. Lancet, The, 2012, 380, 1540-1541.	6.3	9

#	Article	IF	Citations
361	Bacteria in sputum of stable severe asthma and increased airway wall thickness. Respiratory Research, 2012, 13, 35.	1.4	86
362	STAT6 expression in T cells, alveolar macrophages and bronchial biopsies of normal and asthmatic subjects. Journal of Inflammation, 2012, 9, 5.	1.5	20
363	RAGE: a new frontier in chronic airways disease. British Journal of Pharmacology, 2012, 167, 1161-1176.	2.7	76
364	Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma. Journal of Allergy and Clinical Immunology, 2012, 129, 95-103.	1.5	173
365	Increased activation of fibrocytes in patients with chronic obstructive asthma through an epidermal growth factor receptorâ€“dependent pathway. Journal of Allergy and Clinical Immunology, 2012, 129, 1367-1376.	1.5	30
366	Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma. Journal of Allergy and Clinical Immunology, 2012, 130, 877-885.e5.	1.5	70
367	Restoration of Corticosteroid Sensitivity by p38 Mitogen Activated Protein Kinase Inhibition in Peripheral Blood Mononuclear Cells from Severe Asthma. PLoS ONE, 2012, 7, e41582.	1.1	100
368	Genome-wide association study to identify genetic determinants of severe asthma. Thorax, 2012, 67, 762-768.	2.7	169
369	The investigation of severe asthma to define phenotypes. Clinical and Experimental Allergy, 2012, 42, 678-692.	1.4	31
370	Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Medicine, 2011, 3, 43.	3.6	181
371	Importance of hedgehog interacting protein and other lung function genes in asthma. Journal of Allergy and Clinical Immunology, 2011, 127, 1457-1465.	1.5	115
372	Safety of investigative bronchoscopy in the Severe Asthma Research Program. Journal of Allergy and Clinical Immunology, 2011, 128, 328-336.e3.	1.5	65
373	Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD. Expert Review of Respiratory Medicine, 2011, 5, 9-16.	1.0	6
374	Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nature Genetics, 2011, 43, 887-892.	9.4	736
375	The Sixth 2010 London International Symposium on Cough: A translational approach. Pulmonary Pharmacology and Therapeutics, 2011, 24, 261-262.	1.1	2
376	Chronic â€˜cough hypersensitivity syndromeâ€™: A more precise label for chronic cough. Pulmonary Pharmacology and Therapeutics, 2011, 24, 267-271.	1.1	149
377	Cardio- and cerebrovascular safety of indacaterol vsÂformoterol, salmeterol, tiotropium and placebo in COPD. Respiratory Medicine, 2011, 105, 571-579.	1.3	67
378	Pro-oxidant iron in exhaled breath condensate: A potential excretory mechanism. Respiratory Medicine, 2011, 105, 1290-1295.	1.3	12

#	Article	IF	Citations
379	Rare Beta2-Adrenergic Receptor Gene Polymorphisms In Asthma Cases And Controls From The Severe Asthma Research Program. , 2011, , .		0
380	Determinants of Exhaled Breath Condensate pH in a Large Population With Asthma. Chest, 2011, 139, 328-336.	0.4	61
381	p38 Mitogen-Activated Protein Kinase Pathways in Asthma and COPD. Chest, 2011, 139, 1470-1479.	0.4	200
382	EMMPRIN (CD147) regulation of MMPâ€9 in bronchial epithelial cells in COPD. Respirology, 2011, 16, 705-712.	1.3	34
383	Outdoor air pollution and respiratory health in Asia. Respirology, 2011, 16, 1023-1026.	1.3	65
384	Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax, 2011, 66, 910-917.	2.7	294
385	COUGH: consolidating a mature field for the next 5 years. Cough, 2011, 7, 1.	2.7	5
386	Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax, 2011, 66, 521-527.	2.7	148
387	Oxidative Stressâ€“induced Antibodies to Carbonyl-modified Protein Correlate with Severity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 796-802.	2.5	159
388	Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids. European Respiratory Journal, 2011, 37, 933-942.	3.1	35
389	Transforming Growth Factor-Î² and Nuclear Factor E2â€“related Factor 2 Regulate Antioxidant Responses in Airway Smooth Muscle Cells. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 894-903.	2.5	73
390	Chromosome 17q21 SNP and severe asthma. Journal of Human Genetics, 2011, 56, 97-98.	1.1	43
391	A model of chronic inflammation and pulmonary emphysema after multiple ozone exposures in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L691-L700.	1.3	66
392	Hydrogen Sulfide Inhibits Proliferation and Release of IL-8 from Human Airway Smooth Muscle Cells. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 746-752.	1.4	77
393	TGF-Î² regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L295-L304.	1.3	163
394	Detrimental Effects of Environmental Tobacco Smoke in Relation to Asthma Severity. PLoS ONE, 2011, 6, e18574.	1.1	96
395	Immune Response to Mycobacterium tuberculosis Infection in the Parietal Pleura of Patients with Tuberculous Pleurisy. PLoS ONE, 2011, 6, e22637.	1.1	21
396	Bronchial hyperresponsiveness and lung inflammation induced by allergic immune response and oxidative stress: role of innate and adaptive immune responses. , 2011, , 117-138.		0

#	Article	IF	Citations
397	Increased Expression Of Aquaporin 5 In Bronchial Glands Of Smokers With Or Without COPD. , 2010, , .		0
398	Increased Deposition Of Activated Complement In Peripheral Lung Vessels Of Smokers. , 2010, , .		0
399	Pharmacological studies of the mechanism and function of interleukin-1Î²-induced miRNA-146a expression in primary human airway smooth muscle. Respiratory Research, 2010, 11, 68.	1.4	74
400	Corticosteroid suppression of lipoxin A4 and leukotriene B4from alveolar macrophages in severe asthma. Respiratory Research, 2010, 11, 71.	1.4	63
401	Hydrogen Sulfide Inhibits Proliferation and Release of IL-8 from Human Airway Smooth Muscle Cells. Free Radical Biology and Medicine, 2010, 49, S52.	1.3	0
402	Predicting Intermediate Phenotypes in Asthma Using Bronchoalveolar Lavageâ€Derived Cytokines. Clinical and Translational Science, 2010, 3, 147-157.	1.5	62
403	Cigarette Smoke Exposure Alters mSin3a and Mi-2Î±/Î² Expression; implications in the control of pro-inflammatory gene transcription and glucocorticoid function. Journal of Inflammation, 2010, 7, 33.	1.5	7
404	Molecular mechanisms of oxidative stress in airways and lungs with reference to asthma and chronic obstructive pulmonary disease. Annals of the New York Academy of Sciences, 2010, 1203, 85-91.	1.8	87
405	Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology. Internal Medicine Journal, 2010, 40, 323-334.	0.5	50
406	Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease. International Journal of COPD, 2010, 5, 297.	0.9	20
407	Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. European Respiratory Journal, 2010, 35, 750-756.	3.1	102
408	Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Therapeutic Advances in Respiratory Disease, 2010, 4, 19-34.	1.0	43
409	An Integrative Systems Biology Approach to Understanding Pulmonary Diseases. Chest, 2010, 137, 1410-1416.	0.4	135
410	Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD). Current Pharmaceutical Design, 2010, 16, 3554-3573.	0.9	25
411	Use of Exhaled Nitric Oxide Measurement to Identify a Reactive, at-Risk Phenotype among Patients with Asthma. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1033-1041.	2.5	252
412	A role for phosphoinositol 3â€“kinase Î´ in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2010, 125, 1146-1153.	1.5	99
413	Racial differences in biologic predictors of severe asthma: Data from the Severe Asthma Research Program. Journal of Allergy and Clinical Immunology, 2010, 126, 1149-1156.e1.	1.5	45
414	Overcoming Reduced Glucocorticoid Sensitivity in Airway Disease. Drugs, 2010, 70, 929-948.	4.9	33

#	Article	IF	Citations
415	Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 315-323.	2.5	1,820
416	Efficacy of a new once-daily long-acting inhaled Â2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax, 2010, 65, 473-479.	2.7	252
417	Oxidative/nitrosative stress selectively altered A_{2B}adenosine receptors in chronic obstructive pulmonary disease. FASEB Journal, 2010, 24, 1192-1204.	0.2	15
418	Down-regulation of insulin-like growth factor I (IGF-I) in the mouse diaphragm during sepsis. Chang Gung Medical Journal, 2010, 33, 501-8.	0.7	3
419	Diminished sarco/endoplasmic reticulum Ca²⁺ATPase (SERCA) expression contributes to airway remodelling in bronchial asthma. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10775-10780.	3.3	136
420	Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD. Thorax, 2009, 64, 968-975.	2.7	79
421	Inhaled corticosteroids as combination therapy with Î²-adrenergic agonists in airways disease: present and future. European Journal of Clinical Pharmacology, 2009, 65, 853-871.	0.8	115
422	Inflammatory biomarkers in airways of patients with severe asthma compared with nonâ€severe asthma. Clinical and Experimental Allergy, 2009, 39, 1668-1676.	1.4	68
423	T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clinical and Experimental Immunology, 2009, 157, 316-324.	1.1	283
424	Activation of NFâ€ÎºB transcription factor in asthma death. Histopathology, 2009, 54, 507-509.	1.6	19
425	MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. Histopathology, 2009, 55, 321-331.	1.6	83
426	Road ahead to respiratory health: Experts chart future research directions. Respirology, 2009, 14, 625-636.	1.3	12
427	The 2008 Fifth International Cough Symposium: Mechanisms and treatment. Pulmonary Pharmacology and Therapeutics, 2009, 22, 57-58.	1.1	3
428	Role of cathepsin S in ozone-induced airway hyperresponsiveness and inflammation. Pulmonary Pharmacology and Therapeutics, 2009, 22, 27-32.	1.1	30
429	Semantics and types of cough. Pulmonary Pharmacology and Therapeutics, 2009, 22, 139-142.	1.1	31
430	Capsaicin cough sensitivity in smokers with and without airflow obstruction. Respiratory Medicine, 2009, 103, 786-790.	1.3	30
431	Postnasal drip and chronic cough: An open interventional study. Respiratory Medicine, 2009, 103, 1700-1705.	1.3	36
432	Expression of transforming growth factor-Î² (TGF-Î²) in chronic idiopathic cough. Respiratory Research, 2009, 10, 40.	1.4	45

#	Article	IF	Citations
433	Mediator Antagonists. , 2009, , 655-662.		0
434	Inter-disease Comparison of Research Quantity and Quality: Bronchial Asthma and Chronic Obstructive Pulmonary Disease. Journal of Asthma, 2009, 46, 147-152.	0.9	22
435	Cough: Setting the Scene. Handbook of Experimental Pharmacology, 2009, , 1-21.	0.9	12
436	Clinical Cough VI: The Need for New Therapies for Cough: Disease-Specific and Symptom-Related Antitussives. Handbook of Experimental Pharmacology, 2009, , 343-368.	0.9	17
437	MicroRNA Expression Profiling in Mild Asthmatic Human Airways and Effect of Corticosteroid Therapy. PLoS ONE, 2009, 4, e5889.	1.1	170
438	Neutrophils and Their Mediators in Asthma and Allergic Disease. , 2009, , 179-193.		1
439	Airway Smooth Muscle Dysfunction in Asthma. , 2009, , 377-400.		0
440	Pharmacology and therapeutics of cough. Preface. Handbook of Experimental Pharmacology, 2009, , v-vi.	0.9	5
441	Steroid resistance in asthma: Mechanisms and treatment options. Current Allergy and Asthma Reports, 2008, 8, 171-178.	2.4	90
442	Currently Available Cough Suppressants for Chronic Cough. Lung, 2008, 186, 82-87.	1.4	37
443	Role of p38 mitogen-activated protein kinase in ozone-induced airway hyperresponsiveness and inflammation. European Journal of Pharmacology, 2008, 600, 117-122.	1.7	35
444	Differential regulation of CCL-11/eotaxin-1 and CXCL-8/IL-8 by Gram-positive and Gram-negative bacteria in human airway smooth muscle cells. Respiratory Research, 2008, 9, 30.	1.4	28
445	Dose-dependent inhibition of allergic inflammation and bronchial hyperresponsiveness by budesonide in ovalbumin-sensitised Brown-Norway rats. Pulmonary Pharmacology and Therapeutics, 2008, 21, 98-104.	1.1	5
446	Fluticasone, but not salmeterol, reduces cigarette smoke-induced production of interleukin-8 in human airway smooth muscle. Pulmonary Pharmacology and Therapeutics, 2008, 21, 292-297.	1.1	16
447	Is TRPV1 a useful target in respiratory diseases?. Pulmonary Pharmacology and Therapeutics, 2008, 21, 833-839.	1.1	44
448	Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study. Respiratory Medicine, 2008, 102, 1371-1378.	1.3	79
449	Efficacy of a cell phone-based exercise programme for COPD. European Respiratory Journal, 2008, 32, 651-659.	3.1	150
450	Matrix metalloproteinases in airways inflammation of asthma and chronic obstructive pulmonary disease. , 2008, , 21-37.		0

#	Article	IF	Citations
451	Prevalence, pathogenesis, and causes of chronic cough. Lancet, The, 2008, 371, 1364-1374.	6.3	524
452	Management of chronic cough. Lancet, The, 2008, 371, 1375-1384.	6.3	144
453	New targets for drug development in asthma. Lancet, The, 2008, 372, 1073-1087.	6.3	223
454	Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. European Respiratory Journal, 2008, 31, 1334-1356.	3.1	475
455	Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax, 2008, 63, 784-790.	2.7	217
456	Effect of Î²₂-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 295, L505-L514.	1.3	57
457	Modulation of ozone-induced airway hyperresponsiveness and inflammation by interleukin-13. European Respiratory Journal, 2008, 32, 571-578.	3.1	29
458	Glucocorticoid suppression of CX 3 CL1 (fractalkine) by reduced gene promoter recruitment of NFâ€ÎºB. FASEB Journal, 2008, 22, 1807-1816.	0.2	48
459	Alterations of the Arginine Metabolome in Asthma. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 673-681.	2.5	116
460	Increased Circulating Fibrocytes in Asthma with Chronic Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 583-591.	2.5	164
461	Airway Lipoxin A₄Generation and Lipoxin A₄Receptor Expression Are Decreased in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 574-582.	2.5	215
462	Omalizumab for the treatment of severe allergic asthma. Expert Review of Clinical Immunology, 2008, 4, 543-548.	1.3	3
463	Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. Journal of Applied Physiology, 2008, 104, 394-403.	1.2	270
464	ERS guidelines on the assessment of cough. European Respiratory Journal, 2007, 29, 1256-1276.	3.1	567
465	Expression and activation of TGF-Â isoforms in acute allergen-induced remodelling in asthma. Thorax, 2007, 62, 307-313.	2.7	84
466	Should treatments for asthma be aimed at the airway smooth muscle?. Expert Review of Respiratory Medicine, 2007, 1, 209-217.	1.0	10
467	Repeated Allergen Inhalation Induces Cytoskeletal Remodeling in Smooth Muscle from Rat Bronchioles. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 721-727.	1.4	21
468	IL4RÎ±Mutations Are Associated with Asthma Exacerbations and Mast Cell/IgE Expression. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 570-576.	2.5	133

#	Article	IF	Citations
469	Inhibition of Airway Smooth Muscle Adhesion and Migration by the Disintegrin Domain of ADAM-15. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 494-500.	1.4	24
470	Safety and Efficacy of Bronchial Thermoplasty in Symptomatic, Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1185-1191.	2.5	387
471	Epithelial Cell Proliferation Contributes to Airway Remodeling in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 138-145.	2.5	208
472	Attenuation of Ozone-Induced Airway Inflammation and Hyper-Responsiveness by c-Jun NH2 Terminal Kinase Inhibitor SP600125. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 351-359.	1.3	56
473	Review Series: Chronic cough: Future directions in chronic cough: mechanisms and antitussives. Chronic Respiratory Disease, 2007, 4, 159-165.	1.0	27
474	Corticosteroid Inhibition of Growth-Related Oncogene Protein-Î± via Mitogen-Activated Kinase Phosphatase-1 in Airway Smooth Muscle Cells. Journal of Immunology, 2007, 178, 7366-7375.	0.4	82
475	Effective antitussives for the cough patient: An unmet need. Pulmonary Pharmacology and Therapeutics, 2007, 20, 438-445.	1.1	29
476	Cough. Pulmonary Pharmacology and Therapeutics, 2007, 20, 305-306.	1.1	10
477	Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respiratory Medicine, 2007, 101, 1483-1492.	1.3	262
478	Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Journal of Allergy and Clinical Immunology, 2007, 119, 405-413.	1.5	838
479	Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. Journal of Allergy and Clinical Immunology, 2007, 120, 1324-1331.	1.5	342
480	Respiratory Effects of Exposure to Diesel Traffic in Persons with Asthma. New England Journal of Medicine, 2007, 357, 2348-2358.	13.9	756
481	Mechanisms of induction of airway smooth muscle hyperplasia by transforming growth factor-Î². American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 293, L245-L253.	1.3	101
482	Role of TLR2, TLR4, and MyD88 in murine ozone-induced airway hyperresponsiveness and neutrophilia. Journal of Applied Physiology, 2007, 103, 1189-1195.	1.2	100
483	Inhibition of citric acid- and capsaicin-induced cough by novel TRPV-1 antagonist, V112220, in guinea-pig. Cough, 2007, 3, 10.	2.7	33
484	Complete inhibition of allergic airway inflammation and remodelling in quadruple IL-4/5/9/13?/?mice. Clinical and Experimental Allergy, 2007, 37, 070831211107003-???.	1.4	39
485	Alteration of Adenosine Receptors in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 398-406.	2.5	101
486	American College of Chest Physicians' cough guidelines. Lancet, The, 2006, 367, 981-982.	6.3	16

#	Article	IF	Citations
487	Beclometasone Dipropionate/Formoterol in an HFA-Propelled Pressurised Metered-Dose Inhaler. Drugs, 2006, 66, 1484-1485.	4.9	0
488	Blood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapy. Respiratory Research, 2006, 7, 59.	1.4	79
489	Update on glucocorticoid action and resistance. Journal of Allergy and Clinical Immunology, 2006, 117, 522-543.	1.5	343
490	Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. Journal of Allergy and Clinical Immunology, 2006, 118, 641-648.	1.5	134
491	Investor protection and the liquidity of cross-listed securities: Evidence from the ADR market. Journal of Banking and Finance, 2006, 30, 1485-1505.	1.4	69
492	Measurement of cough. Respiratory Physiology and Neurobiology, 2006, 152, 329-339.	0.7	32
493	Integrin binding characteristics of the disintegrin-like domain of ADAM-15. Thrombosis and Haemostasis, 2006, 96, 642-651.	1.8	11
494	Cytokines as Targets in Chronic Obstructive Pulmonary Disease. Current Drug Targets, 2006, 7, 675-681.	1.0	114
495	Gene and protein expression of protease-activated receptor 2 in structural and inflammatory cells in the nasal mucosa in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2006, 36, 1039-1048.	1.4	29
496	Phosphodiesterase inhibitors in airways disease. European Journal of Pharmacology, 2006, 533, 110-117.	1.7	216
497	Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsiveness. European Journal of Pharmacology, 2006, 544, 160-167.	1.7	47
498	Intrinsic Differences of the Airway Epithelium in Childhood Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1066-1067.	2.5	4
499	Relative Corticosteroid Insensitivity of Peripheral Blood Mononuclear Cells in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 134-141.	2.5	247
500	Neutrophil-Derived Elastase Induces TGF-Î²1 Secretion in Human Airway Smooth Muscle via NF-ÎºB Pathway. American Journal of Respiratory Cell and Molecular Biology, 2006, 35, 407-414.	1.4	81
501	Validation of the Anti-Inflammatory Properties of Small-Molecule IÎºB Kinase (IKK)-2 Inhibitors by Comparison with Adenoviral-Mediated Delivery of Dominant-Negative IKK1 and IKK2 in Human Airways Smooth Muscle. Molecular Pharmacology, 2006, 70, 697-705.	1.0	71
502	GRO-Î± regulation in airway smooth muscle by IL-1Î² and TNF-Î±: role of NF-ÎºB and MAP kinases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 291, L66-L74.	1.3	56
503	Capsaicin cough sensitivity in bronchiectasis. Thorax, 2006, 61, 706-709.	2.7	36
504	Effect of Transforming Growth Factor-Î² Receptor I Kinase Inhibitor 2,4-Disubstituted Pteridine (SD-208) in Chronic Allergic Airway Inflammation and Remodeling. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 586-594.	1.3	66

#	Article	IF	Citations
505	Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. European Respiratory Journal, 2006, 27, 230-232.	3.1	37
506	Regulation of human lung epithelial cell numbers by diesel exhaust particles. European Respiratory Journal, 2006, 27, 705-713.	3.1	68
507	Salmeterol/fluticasone combination in the treatment of COPD. International Journal of COPD, 2006, 1, 235-242.	0.9	5
508	H+/K+-ATPase (proton pump) inhibitors dampen increased cough reflex: more than gastric acid suppression. Clinical and Experimental Allergy, 2005, 35, 245-246.	1.4	2
509	Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. European Journal of Pharmacology, 2005, 506, 273-283.	1.7	67
510	Cough: meeting the needs of a growing field. Cough, 2005, 1, 1.	2.7	18
511	No effect of omeprazole on pH of exhaled breath condensate in cough associated with gastro-oesophageal reflux. Cough, 2005, 1, 10.	2.7	17
512	Inflammatory Mediators in Chronic Obstructive Pulmonary Disease. Inflammation and Allergy: Drug Targets, 2005, 4, 619-625.	3.1	138
513	Regulation of TGF-Î²1-induced connective tissue growth factor expression in airway smooth muscle cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L68-L76.	1.3	96
514	Bilateral non-traumatic second rib fracture after bilateral first rib resection for TOS. Thorax, 2005, 60, 259-260.	2.7	4
515	Transcriptional down-regulation of neurotrophin-3 in chronic obstructive pulmonary disease. Biological Chemistry, 2005, 386, 53-9.	1.2	12
516	The Role of Airway Smooth Muscle in the Pathogenesis of Airway Wall Remodeling in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2005, 2, 347-354.	3.5	95
517	Induction of Human Airway Smooth Muscle Apoptosis by Neutrophils and Neutrophil Elastase. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 334-341.	1.4	38
518	Correlation of Systemic Superoxide Dismutase Deficiency to Airflow Obstruction in Asthma. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 306-313.	2.5	148
519	Drugs to suppress cough. Expert Opinion on Investigational Drugs, 2005, 14, 19-27.	1.9	40
520	Signalling and transcriptional regulation in inflammatory and immune cells: importance in lung biology and disease. European Respiratory Journal, 2005, 26, 762-763.	3.1	5
521	Effects of Cigarette Smoke on Pulmonary Homeostasis. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 167-167.	1.4	6
522	Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respiratory Medicine, 2005, 99, 200-207.	1.3	83

#	Article	IF	Citations
523	Asthme corticorÃ©sistant et corticodÃ©pendantÂ: quelles solutionsÂ?. Revue Francaise D'allergologie Et D'immunologie Clinique, 2005, 45, 17-24.	0.1	2
524	Induction and regulation of matrix metalloproteinase-12in human airway smooth muscle cells. Respiratory Research, 2005, 6, 148.	1.4	86
525	Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. Respiratory Research, 2005, 6, 42.	1.4	64
526	Cigarette smoke induces IL-8, but inhibits eotaxin and RANTES release from airway smooth muscle. Respiratory Research, 2005, 6, 74.	1.4	82
527	Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features. Journal of Allergy and Clinical Immunology, 2005, 115, 989-996.	1.5	58
528	Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2005, 116, 1028-1035.	1.5	127
529	Nature of airway inflammation and remodeling in chronic cough. Journal of Allergy and Clinical Immunology, 2005, 116, 565-570.	1.5	137
530	Molecular Mechanisms of Pulmonary Peptidomimetic Drug and Peptide Transport. American Journal of Respiratory Cell and Molecular Biology, 2004, 30, 251-260.	1.4	76
531	Mitogen-Activated Protein Kinase Modulation of Nuclear Factor-ÎºBâ€“Induced Granulocyte Macrophageâ€“Colony-Stimulating Factor Release from Human Alveolar Macrophages. American Journal of Respiratory Cell and Molecular Biology, 2004, 30, 342-349.	1.4	39
532	Airway Obstruction in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2004, 351, 1459-1461.	13.9	15
533	Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 583-593.	2.5	588
534	The diagnosis and management of chronic cough. European Respiratory Journal, 2004, 24, 481-492.	3.1	454
535	Failure of sputum eosinophilia after eotaxin inhalation in asthma. Thorax, 2004, 59, 372-375.	2.7	5
536	Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax, 2004, 59, 550-556.	2.7	170
537	Parameters associated with persistent airflow obstruction in chronic severe asthma. European Respiratory Journal, 2004, 24, 122-128.	3.1	208
538	Increased Expression of Transient Receptor Potential Vanilloid-1 in Airway Nerves of Chronic Cough. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1276-1280.	2.5	365
539	Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma. Expert Opinion on Pharmacotherapy, 2004, 5, 439-446.	0.9	14
540	Fractalkine/CX3CL1 production by human airway smooth muscle cells: induction by IFN-Î³ and TNF-Î± and regulation by TGF-Î² and corticosteroids. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 287, L1230-L1240.	1.3	88

#	Article	IF	Citations
541	Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough. Thorax, 2004, 59, 608-612.	2.7	104
542	Formoterol protects against platelet-activating factor-induced effects in asthma. European Respiratory Journal, 2004, 23, 71-75.	3.1	16
543	Differential expression of IL-10 receptor by epithelial cells and alveolar macrophages. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 505-514.	2.7	32
544	Maximal airway plateau responses and eosinophils in cough variant asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 1053-1054.	2.7	0
545	Resolution of allergic airways inflammation but persistence of airway smooth muscle proliferation after repeated allergen exposures. Clinical and Experimental Allergy, 2004, 34, 213-220.	1.4	23
546	Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical and Experimental Allergy, 2004, 34, 632-638.	1.4	490
547	Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology, 2004, 45, 477-484.	1.6	141
548	Effect of an inhibitor of Jun N-terminal protein kinase, SP600125, in single allergen challenge in sensitized rats. Immunology, 2004, 112, 446-453.	2.0	44
549	Mitogen-activated protein kinase signalling pathways in IL-1Î² -dependent rat airway smooth muscle proliferation. British Journal of Pharmacology, 2004, 143, 1042-1049.	2.7	39
550	Effects of interleukin-1Î², interleukin-13 and transforming growth factor-Î² on gene expression in human airway smooth muscle using gene microarrays. European Journal of Pharmacology, 2004, 497, 255-265.	1.7	52
551	Characteristics and outcome for admissions to adult, general critical care units with acute severe asthma: a secondary analysis of the ICNARC Case Mix Programme Database. Critical Care, 2004, 8, R112.	2.5	57
552	STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. European Respiratory Journal, 2004, 24, 78-85.	3.1	120
553	Models of chronic obstructive pulmonary disease. Respiratory Research, 2004, 5, 18.	1.4	107
554	Combination Therapy of Long-Acting ??2-Adrenoceptor Agonists and Corticosteroids for Asthma. Treatments in Respiratory Medicine, 2004, 3, 279-289.	1.4	40
555	Inhibition of chemokine production from human airway smooth muscle cells by fluticasone, budesonide and beclomethasone. Pulmonary Pharmacology and Therapeutics, 2004, 17, 41-47.	1.1	16
556	Neuropeptide Y (NPY). Pulmonary Pharmacology and Therapeutics, 2004, 17, 173-180.	1.1	54
557	Airway inflammation and remodelling changes in patients with chronic cough: do they tell us about the cause of cough?. Pulmonary Pharmacology and Therapeutics, 2004, 17, 441-446.	1.1	33
558	Cough as a symptom. Pulmonary Pharmacology and Therapeutics, 2004, 17, 329-332.	1.1	11

#	Article	IF	Citations
559	Cough: acute and chronic. Pulmonary Pharmacology and Therapeutics, 2004, 17, 327.	1.1	2
560	Acute and chronic cough. Pulmonary Pharmacology and Therapeutics, 2004, 17, 471-473.	1.1	7
561	Effect of cigarette smoking on haem-oxygenase expression in alveolar macrophages. Respiratory Medicine, 2004, 98, 530-535.	1.3	7
562	Summary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma. Respiratory Medicine, 2004, 98, 479-487.	1.3	21
563	Adenosine 5â€²-monophosphate increases levels of leukotrienes in breath condensate in asthma. Respiratory Medicine, 2004, 98, 651-655.	1.3	23
564	Protease-activated receptor 2 in regulation of bronchomotor tone: Effect of tobacco smoking. Life Sciences, 2004, 75, 991-1002.	2.0	6
565	Mucus and fatal asthma. American Journal of Medicine, 2004, 116, 66-67.	0.6	18
566	Effects of cyclosporin A and a rapamycin derivative (SAR943) on chronic allergic inflammation in sensitized rats. Immunology, 2003, 109, 461-467.	2.0	27
567	Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma. British Journal of Pharmacology, 2003, 138, 1147-1155.	2.7	11
568	Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells. British Journal of Pharmacology, 2003, 139, 1228-1234.	2.7	92
569	Allergen-induced inflammation and airway epithelial and smooth muscle cell proliferation: role of Jun N-terminal kinase. British Journal of Pharmacology, 2003, 140, 1373-1380.	2.7	56
570	Distribution of Respiratory Mucin Proteins in Human Nasal Mucosa. Laryngoscope, 2003, 113, 520-524.	1.1	73
571	Effect of acute and chronic inflammatory stimuli on expression of protease-activated receptors 1 and 2 in alveolar macrophages. Journal of Allergy and Clinical Immunology, 2003, 111, 367-373.	1.5	55
572	Systematic assessment of difficult-to-treat asthma. European Respiratory Journal, 2003, 22, 478-483.	3.1	271
573	Fundamentals of pulmonary drug delivery. Respiratory Medicine, 2003, 97, 382-387.	1.3	214
574	Regulation of protease-activated receptor-1 in mononuclear cells by neutrophil proteases. Respiratory Medicine, 2003, 97, 228-233.	1.3	16
575	Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax, 2003, 58, 348-351.	2.7	179
576	Murine models of asthma. European Respiratory Journal, 2003, 22, 374-382.	3.1	189

#	Article	IF	Citations
577	Role of Nitric Oxide in Chronic Allergen-Induced Airway Cell Proliferation and Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 22-29.	1.3	57
578	Neutrophil airway influx by platelet-activating factor in asthma: role of adhesion molecules and LTB4 expression. European Respiratory Journal, 2003, 22, 290-297.	3.1	27
579	Severe acute respiratory syndrome: global initiatives for disease diagnosis. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 845-852.	0.2	38
580	Individual cytokines contributing to asthma pathophysiology: valid targets for asthma therapy?. Current Opinion in Investigational Drugs, 2003, 4, 1320-6.	2.3	6
581	A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8921-8926.	3.3	461
582	Fluticasone propionate attenuates platelet-activating factor-induced gas exchange defects in mild asthma. European Respiratory Journal, 2002, 19, 872-878.	3.1	17
583	Matrix Metalloproteinase-9 Expression in Asthma. Chest, 2002, 122, 1543-1552.	0.4	162
584	IL-5 in asthma. Thorax, 2002, 57, 751-751.	2.7	4
585	Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax, 2002, 57, 55-60.	2.7	72
586	Increased p21CIP1/WAF1and B Cell Lymphoma Leukemia-xLExpression and Reduced Apoptosis in Alveolar Macrophages from Smokers. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 724-731.	2.5	121
587	Title is missing!. Pharmaceutical Medicine, 2002, 16, 115-127.	0.4	1
588	Therapy for Cough: Active Agents. Pulmonary Pharmacology and Therapeutics, 2002, 15, 335-338.	1.1	32
589	Assessment and Measurement of Cough: the Value of New Tools. Pulmonary Pharmacology and Therapeutics, 2002, 15, 267-272.	1.1	35
590	Inhaled corticosteroid dose-reducing effect of omalizumab in patients with controlled, severe asthma according to usage of inhaled long-acting beta-agonists. Journal of Allergy and Clinical Immunology, 2002, 109, S239-S239.	1.5	3
591	Expression and Activity of Histone Deacetylases in Human Asthmatic Airways. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 392-396.	2.5	296
592	Increased expression of nuclear factor-ÂB in bronchial biopsies from smokers and patients with COPD. European Respiratory Journal, 2002, 20, 556-563.	3.1	383
593	p38 Mitogen-activated protein kinaseâ€“induced glucocorticoid receptor phosphorylation reduces its activity: Role in steroid-insensitive asthma. Journal of Allergy and Clinical Immunology, 2002, 109, 649-657.	1.5	378
594	Cough: potential pharmacological developments. Expert Opinion on Investigational Drugs, 2002, 11, 955-963.	1.9	13

#	Article	IF	Citations
595	Attenuated Production of Intracellular IL-10 and IL-12 in Monocytes from Patients with Severe Asthma. Clinical Immunology, 2002, 102, 258-266.	1.4	50
596	Expression of MUC5AC and MUC5B mucins in normal and cystic fibrosis lung. Respiratory Medicine, 2002, 96, 81-86.	1.3	160
597	Regulation of kinin receptors in airway epithelial cells by inflammatory cytokines and dexamethasone. European Journal of Pharmacology, 2002, 441, 193-202.	1.7	29
598	Effect of topical immunomodulators on acute allergic inflammation and bronchial hyperresponsiveness in sensitised rats. European Journal of Pharmacology, 2002, 437, 187-194.	1.7	16
599	Role of nitric oxide in allergic inflammation and bronchial hyperresponsiveness. European Journal of Pharmacology, 2002, 452, 123-133.	1.7	63
600	Expression of respiratory mucins in fatal status asthmaticus and mild asthma. Histopathology, 2002, 40, 367-373.	1.6	149
601	Current and potential improvements in the treatment of asthma from increased understanding of airway pathophysiology. Allergology International, 2002, 51, 153-166.	1.4	1
602	Protease-activated receptors in human airways: Upregulation of PAR-2 in respiratory epithelium from patients with asthma. Journal of Allergy and Clinical Immunology, 2001, 108, 797-803.	1.5	251
603	Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies. European Respiratory Journal, 2001, 18, 466-473.	3.1	72
604	Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clinical and Experimental Allergy, 2001, 31, 893-902.	1.4	73
605	Low-dose theophylline does not exert its anti-inflammatory effects in mild asthma through upregulation of interleukin-10 in alveolar macrophages. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 1087-1090.	2.7	22
606	Severe asthma: definition and mechanisms. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 825-840.	2.7	48
607	Pathophysiological Mechanisms of Asthma: Application of Cell and Molecular Biology Techniques. Molecular Biotechnology, 2001, 18, 213-232.	1.3	12
608	Interleukin-5 in growth and differentiation of blood eosinophil progenitors in asthma: effect of glucocorticoids. British Journal of Pharmacology, 2001, 134, 1539-1547.	2.7	21
609	RANTES release by human airway smooth muscle: effects of prostaglandin E2 and fenoterol. European Journal of Pharmacology, 2001, 433, 231-235.	1.7	21
610	Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax, 2001, 56, 935-940.	2.7	27
611	[50] Induction of nuclear factor-Î¹B by exposure to ozone and inhibition by glucocorticoids. Methods in Enzymology, 2000, 319, 551-562.	0.4	9
612	The airway smooth muscle cell: a major contributor to asthma?. European Respiratory Journal, 2000, 15, 438-439.	3.1	15

#	Article	IF	Citations
613	Airway smooth muscle cells: contributing to and regulating airway mucosal inflammation?. European Respiratory Journal, 2000, 15, 961-968.	3.1	124
614	Involvement of haemoxygenase-1 in ozone-induced airway inflammation and hyperresponsiveness. European Journal of Pharmacology, 2000, 399, 229-234.	1.7	21
615	Future treatments of allergic diseases and asthma. British Medical Bulletin, 2000, 56, 1037-1053.	2.7	26
616	Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax, 2000, 55, 184-188.	2.7	114
617	Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax, 2000, 55, 837-841.	2.7	67
618	Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsÃ¬veness, and the late asthmatic response. Lancet, The, 2000, 356, 2144-2148.	6.3	1,700
619	Ceramide Induction of COX-2 and PGE2 in Pulmonary A549 Cells Does Not Involve Activation of NF-ÎºB. Biochemical and Biophysical Research Communications, 2000, 277, 675-679.	1.0	34
620	Compliance with an oral asthma medication: a pilot study using an electronic monitoring device. Respiratory Medicine, 2000, 94, 852-858.	1.3	31
621	New immunological approaches and cytokine targetsin asthma and allergy. European Respiratory Journal, 2000, 16, 1158-1174.	3.1	24
622	Effect of CD8+Tâ€cell depletion on bronchial hyperâ€responsiveness and inflammation in sensitized and allergenâ€exposed Brownâ€“Norway rats. Immunology, 1999, 96, 416-423.	2.0	49
623	Inhibitory effects of endogenous and exogenous interferon-Î³ on bronchial hyperresponsiveness, allergic inflammation and T-helper 2 cytokines in Brown-Norway rats. Immunology, 1999, 98, 280-288.	2.0	26
624	Induction of eotaxin expression and release from human airway smooth muscle cells by IL-1Î² and TNFÎ±: effects of IL-10 and corticosteroids. British Journal of Pharmacology, 1999, 127, 1145-1150.	2.7	89
625	Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats. British Journal of Pharmacology, 1999, 127, 1151-1158.	2.7	71
626	Inhibition of ozone-induced lung neutrophilia and nuclear factor-ÎºB binding activity by vitamin A in rat. European Journal of Pharmacology, 1999, 377, 63-68.	1.7	16
627	Non-invasive biomarkers of asthma. , 1999, 27, 41-44.		10
628	Increased progenitor cell proliferation in the peripheral blood of patients with bronchial asthma: The role of nitric oxide. Journal of Allergy and Clinical Immunology, 1999, 104, 803-810.	1.5	26
629	Differential regulation of cytokine expression after allergen exposure of sensitized rats by cyclosporin A and corticosteroids: Relationship to bronchial hyperresponsiveness. Journal of Allergy and Clinical Immunology, 1999, 104, 644-652.	1.5	14
630	Difficult/therapyâ€resistant asthmaThe need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. European Respiratory Journal, 1999, 13, 1198.	3.1	313

#	Article	IF	Citations
631	Effects of inhaled furosemide on platelet-activating factor challenge in mild asthma. European Respiratory Journal, 1999, 14, 616.	3.1	15
632	Gas exchange response to a PAF receptor antagonist, SR 27417A, in acute asthma: A pilot study. European Respiratory Journal, 1999, 14, 622.	3.1	20
633	Repeated allergen exposure of sensitized Brown-Norway rats induces airway cell DNA synthesis and remodelling. European Respiratory Journal, 1999, 14, 633.	3.1	82
634	The role of new asthma treatments. Allergology International, 1998, 47, 237-246.	1.4	2
635	Pharmacology of corticosteroids. Respiratory Medicine, 1998, 92, 385-394.	1.3	17
636	Peripheral airways obstruction on high-resolution computed tomography in chronic severe asthma. Respiratory Medicine, 1998, 92, 448-453.	1.3	38
637	Increased exhaled nitric oxide in active pulmonary tuberculosis due to inducible NO synthase upregulation in alveolar macrophages. European Respiratory Journal, 1998, 11, 809-815.	3.1	148
638	Effect of a platelet-activating factor (PAF) antagonist, SR 27417A, on PAF-induced gas exchange abnormalities in mild asthma. European Respiratory Journal, 1998, 11, 835-839.	3.1	16
639	A Comparison of Low-Dose Inhaled Budesonide plus Theophylline and High-Dose Inhaled Budesonide for Moderate Asthma. New England Journal of Medicine, 1997, 337, 1412-1419.	13.9	355
640	Kyphoscoliosis and Bronchial Torsion. Chest, 1997, 111, 1134-1137.	0.4	33
641	Effect of 5-HTA receptor agonist, 8-OH-DPAT, on cough responses in the conscious guinea-pig. European Journal of Pharmacology, 1997, 332, 201-207.	1.7	18
642	Airway inflammation despite loss of bronchial hyper-responsiveness after multiple ozone exposures. Respiratory Medicine, 1997, 91, 47-55.	1.3	12
643	Inducible nitric oxide synthase after sensitization and allergen challenge of Brown Norway rat lung. British Journal of Pharmacology, 1997, 121, 1241-1246.	2.7	55
644	INTERACTION OF OZONE EXPOSURE WITH AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION INDUCED BY TRIMELLITIC ANHYDRIDE IN SENSITIZED GUINEA PIGS. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1997, 51, 77-87.	1.1	2
645	The effect of inhaled K+ channel openers on bronchoconstriction and airway microvascular leakage in anaesthetised guinea pigs. European Journal of Pharmacology, 1996, 296, 81-87.	1.7	9
646	Ozone induction of cytokine-induced neutrophil chemoattractant (CINC) and nuclear factor-Îºb in rat lung: inhibition by corticosteroids. FEBS Letters, 1996, 379, 265-268.	1.3	94
647	Pro-oxidant Iron Is Present in Human Pulmonary Epithelial Lining Fluid: Implications for Oxidative Stress in the Lung. Biochemical and Biophysical Research Communications, 1996, 220, 1024-1027.	1.0	100
648	Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. European Respiratory Journal, 1996, 9, 196-201.	3.1	214

#	Article	IF	Citations
649	Lack of a role for bradykinin in allergen-induced airway microvascular leakage and bronchoconstriction in the guinea pig. Inflammation Research, 1996, 45, 123-126.	1.6	5
650	Methods of Assessing Cough and Antitussives in Man. Pulmonary Pharmacology, 1996, 9, 373-377.	0.5	7
651	Airway neuropeptides and neutral endopeptidase in asthma. Clinical and Experimental Allergy, 1996, 26, 491-493.	1.4	3
652	Bradykininâ€“evoked sensitization of airway sensory nerves: A mechanism for ACEâ€“inhibitor cough. Nature Medicine, 1996, 2, 814-817.	15.2	270
653	Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. European Respiratory Journal, 1995, 8, 1203-1213.	3.1	79
654	Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in Brown-Norway rats. Inflammation Research, 1995, 44, 83-86.	1.6	32
655	Induction of macrophage inflammatory protein 2 gene expression by interleukin 1 beta in rat lung.. Thorax, 1995, 50, 1136-1140.	2.7	24
656	Effects of sodium metabisulphite on guinea pig contractile airway smooth muscle responses in vitro.. Thorax, 1995, 50, 875-879.	2.7	11
657	Inhaled frusemide and exercise-induced bronchoconstriction in children with asthma.. Thorax, 1995, 50, 677-679.	2.7	12
658	Expression of inducible nitric oxide synthase mRNA in Brown Norway rats exposed to ozone: effect of dexamethasone. European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section, 1995, 293, 287-290.	0.8	37
659	Neurogenic goblet cell secretion and bronchoconstriction in guinea pigs sensitised to trimellitic anhydride. European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section, 1995, 292, 127-134.	0.8	4
660	Effect of acetazolamide and amiloride against sodium metabisulphite-induced bronchoconstriction in mild asthma.. Thorax, 1994, 49, 1096-1098.	2.7	8
661	Furosemide and Other Diuretics in Asthma. Journal of Asthma, 1994, 31, 85-92.	0.9	6
662	Effect of interleukin-1Î² on airway hyperresponsiveness and inflammation in sensitized and nonsensitized Brown-Norway rats. Journal of Allergy and Clinical Immunology, 1994, 93, 464-469.	1.5	58
663	Effect of a bradykinin receptor antagonist, HOE 140, against bradykinin- and vagal stimulation-induced airway responses in the guinea-pig. European Journal of Pharmacology, 1994, 251, 137-142.	1.7	15
664	Coughing frequency in patients with persistent cough: assessment using a 24 hour ambulatory recorder. European Respiratory Journal, 1994, 7, 1246-1253.	3.1	274
665	Effect ofÎ²(in2)-adrenoceptor agonists against platelet-activating factor-induced airway microvascular leakage and bronchoconstriction in the guinea pig. Agents and Actions, 1993, 40, 50-56.	0.7	12
666	Role played by NK2 receptor and cyclooxygenase activation in bradykinin B2 receptor mediated-airway effects in guinea pigs. Agents and Actions, 1993, 39, 111-117.	0.7	7

#	Article	IF	Citations
667	Effect of CP-96,345, a non-peptide NK1 receptor antagonist, against substance P-, bradykinin- and allergen-induced airway microvascular leakage and bronchoconstriction in the guinea pig. European Journal of Pharmacology, 1993, 231, 31-38.	1.7	63
668	Effect of a topical corticosteroid on airway hyperresponsiveness and eosinophilic inflammation induced by trimellitic anhydride exposure in sensitized guinea pigs. Journal of Allergy and Clinical Immunology, 1993, 92, 450-456.	1.5	12
669	Corticosteroid Therapy in Asthma: Are Metabolic Considerations Important?. Journal of Asthma, 1992, 29, 299-301.	0.9	0
670	The effect of anion transport inhibitors and extracellular Clâ˜ concentration on eosinophil respiratory burst activity. Biochemical Pharmacology, 1992, 43, 2480-2482.	2.0	11
671	Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet-activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig. European Journal of Pharmacology, 1992, 213, 367-373.	1.7	40
672	Effect of neutral endopeptidase inhibitor on airway function and bronchial responsiveness in asthmatic subjects. European Journal of Clinical Pharmacology, 1992, 42, 491-494.	0.8	15
673	Specific immunological and bronchopulmonary responses following intradermal sensitization to free trimellitic anhydride in guinea pigs. Clinical and Experimental Allergy, 1992, 22, 694-700.	1.4	39
674	Loop diuretics and asthma. Pulmonary Pharmacology, 1992, 5, 1-7.	0.5	29
675	Modulation of neurally mediated airway microvascular leakage in guinea-pig airways byÎ² 2 agonists. Agents and Actions, 1992, 36, 29-32.	0.7	9
676	Detection of bronchiectasis by high-resolution computed tomography in the yellow nail syndrome. Clinical Radiology, 1991, 43, 377-379.	0.5	22
677	Inhaled formoterol inhibits histamine-induced airflow obstruction and airway microvascular leakage. European Journal of Pharmacology, 1991, 193, 35-39.	1.7	57
678	BradykMn-induced airway microvasciilar leakage is potentiated by captopril and phosphoramidon. European Journal of Pharmacology, 1991, 200, 211-217.	1.7	31
679	Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086 in man. Journal of Allergy and Clinical Immunology, 1991, 88, 83-88.	1.5	19
680	Role for platelet-activating factor in asthma. Lipids, 1991, 26, 1277-1279.	0.7	19
681	Pharmacology of airway inflammation in asthma. Lung, 1990, 168, 132-141.	1.4	9
682	Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet, The, 1990, 336, 137-140.	6.3	164
683	Inhibition of the cutaneous response to antigen by a thromâ˜ane-synthetase inhibitor (OKY-046) in allergic dogs. Journal of Allergy and Clinical Immunology, 1989, 84, 206-213.	1.5	2
684	Effect of topical capsaicin on the cutaneous responses to inflammatory mediators and to antigen in man. Journal of Allergy and Clinical Immunology, 1989, 83, 1118-1124.	1.5	35

#	Article	IF	Citations
685	Characterization of platelet-activating factor-induced elevation of cytosolic free calcium concentration in eosinophils. FEBS Letters, 1989, 243, 41-46.	1.3	42
686	Effect of inhaled platelet-activating factor on circulating neutrophils and platelets in vivo and ex vivo in man. Prostaglandins, 1988, 36, 343-354.	1.2	9
687	Ketotifen inhibits the cutaneous but not the airway responses to platelet-activating factor in man. Journal of Allergy and Clinical Immunology, 1988, 81, 1192-1198.	1.5	58
688	Cutaneous allergic response in atopic dogs: Relationship of cellular and histamine responses. Journal of Allergy and Clinical Immunology, 1988, 81, 441-448.	1.5	22
689	Platelet-activating factor as a mediator of allergic disease. Journal of Allergy and Clinical Immunology, 1988, 81, 919-934.	1.5	227
690	Effect of a PAF antagonist, BN52063, on antigen-induced, acute, and late-onset cutaneous responses in atopic subjects. Journal of Allergy and Clinical Immunology, 1988, 82, 236-241.	1.5	63
691	Ozone-induced Bronchial Hyperresponsiveness in the Rat Is Not Accompanied by Neutrophil Influx or Increased Vascular Permeability in the Trachea. The American Review of Respiratory Disease, 1988, 138, 140-144.	2.9	94
692	PAF closely mimics pathology of asthma. Trends in Pharmacological Sciences, 1987, 8, 285-287.	4.0	37
693	EFFECT OF A GINKGOLIDE MIXTURE (BN 52063) IN ANTAGONISING SKIN AND PLATELET RESPONSES TO PLATELET ACTIVATING FACTOR IN MAN. Lancet, The, 1987, 329, 248-251.	6.3	251
694	Cutaneous mast cell heterogeneity: Response to antigen in atopic dogs. Journal of Allergy and Clinical Immunology, 1986, 78, 937-942.	1.5	23
695	Role of inflammation in the hyperreactivity of the airways in asthma.. Thorax, 1986, 41, 657-662.	2.7	235
696	Modulation of cholinergic neurotransmission in canine airways by thromboxane mimetic U46619. European Journal of Pharmacology, 1985, 117, 373-375.	1.7	65
697	Prostaglandin F2Î± increases responsiveness of pulmonary airways in dogs. Prostaglandins, 1984, 28, 537-543.	1.2	42
698	Suppression of prolonged fever during treatment of pulmonary tuberculosis: importance of using twice versus single daily dose of prednisolone. Postgraduate Medical Journal, 1983, 59, 373-375.	0.9	12
699	Acromegaly and Hyperprolactinemia in McCune-Albright Syndrome. American Journal of Diseases of Children, 1983, 137, 134.	0.5	36
700	Cigarette Smoke, Oxidative Stress and Corticosteroid Responsiveness. , 0, , 125-144.		0
701	Glucocorticoid Actions on Airway Smooth Muscle. , 0, , 235-254.		0
702	Altered Properties of Airway Smooth Muscle in Asthma. , 0, , 181-199.		0

#	Article	IF	Citations
703	The Airway Smooth Muscle in Chronic Obstructive Pulmonary Disease (COPD). , 0, , 201-233.		1
704	Asthma Treatments: Effects on the Airway Smooth Muscle. , 0, , 277-302.		4
705	Airway Smooth Muscle Synthesis of Inflammatory Mediators. , 0, , 141-158.		1
706	Corticosteroid Responsiveness in Asthma: Clinical Aspects. , 0, , 89-107.		0
707	Increased Interleukin-17 and Glucocorticoid Receptor-Î² Expression in Interstitial Lung Diseases and Corticosteroid Insensitivity. Frontiers in Immunology, 0, 13, .	2.2	5